{"entity":{"id":"2025","kind":"year","name":"2025 in oncology","aka":["2025"],"tldr":"Everything OnCo dates to 2025: 610 entries, 129 trials reported, 126 papers, 90 landmarks and 78 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"610 dated entries in OnCo fall in 2025: 129 trials reported, 126 papers, 90 landmarks, 78 approvals, 68 regulatory events, 58 papers listed on people's pages, 34 financing rounds, 12 technologies, 8 guideline changes, 5 expected dates, 1 company founded and 1 law or regulation.\n\nOf those, 30 to the day, 46 to the month, 1 to the quarter and 533 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2024","2026"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2025,"events":[{"group":"approval","date":"2025","precision":"year","title":"ArteraAI Prostate approved in US","note":"Localised prostate cancer risk stratification and ADT benefit prediction","from":"artera-ai-prostate","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Atezolizumab approved in England (NICE)","note":"Adjuvant treatment of resected non-small-cell lung cancer after platinum chemotherapy, where PD-L1 is on 50 percent or more of tumour cells and the tumour is not EGFR-mutant or ALK...","from":"atezolizumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Avutometinib + defactinib approved in US","note":"KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy (accelerated)","from":"avutometinib-defactinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Belantamab mafodotin approved in EU","note":"R/R myeloma with BorDex or PomDex; 23 Jul 2025","from":"belantamab-mafodotin","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Belantamab mafodotin approved in US","note":"Relapsed/refractory myeloma after ≥1 prior line, in combination","from":"belantamab-mafodotin","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Belzutifan approved in EU","note":"ccRCC after ≥2 lines; VHL-associated tumours; 12 Feb 2025 (conditional). Conditional marketing authorisation","from":"belzutifan","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Cabozantinib approved in US","note":"Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)","from":"cabozantinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Catumaxomab approved in EU","note":"Intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas not eligible for further systemic therapy (Korjuny)","from":"catumaxomab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Cemiplimab approved in US","note":"Adjuvant high-risk CSCC after surgery and radiation","from":"cemiplimab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Darolutamide approved in US","note":"mHSPC with ADT alone (ARANOTE)","from":"darolutamide","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Datopotamab deruxtecan approved in EU","note":"HR+/HER2- mBC after endocrine + chemo; 4 Apr 2025","from":"datopotamab-deruxtecan","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Datopotamab deruxtecan approved in EU","note":"HR-positive, HER2-negative unresectable or metastatic breast cancer after endocrine therapy and at least one line of chemotherapy; marketing authorisation issued 4 April 2025.","from":"datopotamab-deruxtecan","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Datopotamab deruxtecan approved in US","note":"HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy","from":"datopotamab-deruxtecan","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Datopotamab deruxtecan approved in US","note":"EGFR-mutant NSCLC after EGFR TKI and platinum chemotherapy","from":"datopotamab-deruxtecan","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Dordaviprone approved in US","note":"Recurrent H3 K27M-mutant diffuse midline glioma, age ≥1 (accelerated)","from":"dordaviprone","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Dorocubicel (UM171-expanded cord blood) approved in EU","note":"Adults with haematological malignancies requiring allogeneic HSCT after myeloablative conditioning with no other suitable donor cells","from":"dorocubicel","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Durvalumab approved in England (NICE)","note":"Untreated extensive-stage small-cell lung cancer, with etoposide and either carboplatin or cisplatin.","from":"durvalumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Durvalumab approved in England (NICE)","note":"Resectable non-small-cell lung cancer (4 cm or more, or node positive) without an EGFR mutation or ALK rearrangement, neoadjuvant with platinum chemotherapy then adjuvant alone.","from":"durvalumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Durvalumab approved in England (NICE)","note":"Limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy.","from":"durvalumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Fruquintinib approved in England (NICE)","note":"Metastatic colorectal cancer at third line or later, only when trifluridine-tipiracil with bevacizumab is unsuitable.","from":"fruquintinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Gemcitabine intravesical system (TAR-200) approved in US","note":"BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumours","from":"tar-200","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH) approved in US","note":"PATHWAY 4B5 extended to HER2-ultralow (IHC 0 with membrane staining)","from":"her2-testing-assays","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Illuccix (kit for Ga-68 gozetotide) approved in US","note":"Gozellix kit; selection of patients for PSMA-targeted radioligand therapy","from":"illuccix","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Imetelstat approved in EU","note":"Lower-risk MDS transfusion-dependent anaemia","from":"imetelstat","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Imlunestrant approved in US","note":"ER+/HER2- ESR1-mutated advanced breast cancer after ≥1 line of endocrine therapy","from":"imlunestrant","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Inavolisib approved in EU","note":"PIK3CA-mutant ER+/HER2- mBC with palbociclib + fulvestrant; 18 Jul 2025","from":"inavolisib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Ipilimumab approved in England (NICE)","note":"Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with nivolumab. TA1065, published 28 May 2025.","from":"ipilimumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Lazertinib approved in EU","note":"1L EGFR-mutant NSCLC with amivantamab; 20 Jan 2025","from":"lazertinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Linvoseltamab approved in EU","note":"R/R myeloma ≥3 lines; 23 Apr 2025 (conditional). Conditional marketing authorisation","from":"linvoseltamab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Linvoseltamab approved in US","note":"Relapsed/refractory myeloma after ≥4 lines (accelerated)","from":"linvoseltamab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Lorlatinib approved in England (NICE)","note":"ALK-positive advanced non-small-cell lung cancer not previously treated with an ALK inhibitor.","from":"lorlatinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Lurbinectedin approved in US","note":"First-line maintenance with atezolizumab in ES-SCLC (full approval)","from":"lurbinectedin","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Lutetium-177 vipivotide tetraxetan approved in US","note":"PSMA+ mCRPC after ARPI, before chemotherapy","from":"pluvicto","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Mirdametinib approved in EU","note":"Symptomatic, inoperable plexiform neurofibromas in NF1, age 2 and over (Ezmekly, conditional)","from":"mirdametinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Mirdametinib approved in US","note":"NF1 with symptomatic plexiform neurofibromas not amenable to complete resection, adults and children 2 and over (Gomekli)","from":"mirdametinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Mitomycin C approved in US","note":"Recurrent low-grade intermediate-risk NMIBC (intravesical gel)","from":"mitomycin","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) approved in EU","note":"First-line treatment of metastatic adenocarcinoma of the pancreas (Onivyde pegylated liposomal with oxaliplatin, fluorouracil and leucovorin), listed in the EMA therapeutic indicat...","from":"nalirifox","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Nirogacestat approved in EU","note":"Progressing desmoid tumours","from":"nirogacestat","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Nivolumab approved in England (NICE)","note":"Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab. TA1065, published 28 May 2025, within the marketing authorisation and subject to the comme...","from":"nivolumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Nivolumab approved in US","note":"Unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab. Approved 8 April 2025 on CheckMate 8HW.","from":"nivolumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Obecabtagene autoleucel approved in EU","note":"Relapsed or refractory B-ALL, adults ≥26 years","from":"obecabtagene-autoleucel","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Odronextamab approved in US","note":"R/R follicular lymphoma after ≥2 lines (accelerated)","from":"odronextamab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Olaparib approved in UK","note":"BRCA mutation-positive HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane; NICE TA1040 (12 February 2025) recommends with a commercial a...","from":"olaparib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Osimertinib approved in England (NICE)","note":"Adjuvant treatment of stage IB to IIIA EGFR exon 19 deletion or L858R non-small-cell lung cancer after complete resection.","from":"osimertinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Osimertinib approved in England (NICE)","note":"Untreated advanced EGFR mutation-positive non-small-cell lung cancer, with pemetrexed and platinum-based chemotherapy.","from":"osimertinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Paltusotine approved in US","note":"Acromegaly in adults","from":"paltusotine","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Panitumumab approved in US","note":"KRAS G12C mCRC with sotorasib","from":"panitumumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Pembrolizumab approved in England (NICE)","note":"Adjuvant treatment of non-small-cell lung cancer at high risk of recurrence after complete resection and platinum chemotherapy.","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Penpulimab approved in US","note":"Recurrent or metastatic non-keratinising NPC with cisplatin-gemcitabine; monotherapy after platinum and ≥1 other line","from":"penpulimab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Pirtobrutinib approved in US","note":"Relapsed/refractory CLL/SLL after a covalent BTK inhibitor (traditional approval, BRUIN CLL-321)","from":"pirtobrutinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Repotrectinib approved in EU","note":"ROS1+ NSCLC; NTRK+ solid tumours; 13 Jan 2025 (conditional). Conditional marketing authorisation","from":"repotrectinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Retifanlimab approved in US","note":"Locally recurrent or metastatic anal SCC with carboplatin-paclitaxel; monotherapy after platinum","from":"retifanlimab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Revumenib approved in US","note":"Relapsed/refractory NPM1-mutant AML","from":"revumenib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Satricabtagene autoleucel approved in China","note":"CLDN18.2+ advanced gastric/GEJ adenocarcinoma, previously treated","from":"satricabtagene-autoleucel","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Savolitinib approved in China","note":"With osimertinib in EGFR-mutant NSCLC with MET amplification after EGFR TKI (SACHI)","from":"savolitinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Selpercatinib approved in England (NICE)","note":"Previously treated RET fusion-positive advanced non-small-cell lung cancer not previously treated with a RET inhibitor.","from":"selpercatinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Serplulimab approved in EU","note":"First-line ES-SCLC with carboplatin-etoposide","from":"serplulimab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Sevabertinib approved in US","note":"HER2 TKD-mutant non-squamous NSCLC after prior systemic therapy (accelerated)","from":"sevabertinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Sonrotoclax approved in China","note":"Relapsed/refractory MCL and CLL/SLL after BTK inhibitor","from":"sonrotoclax","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Sotorasib approved in US","note":"KRAS G12C colorectal cancer with panitumumab","from":"sotorasib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Sotorasib approved in US","note":"KRAS G12C-mutated metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, with panitumumab. Approved 16 January 2025 on CodeBreaK 300.","from":"sotorasib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Sunvozertinib approved in US","note":"Locally advanced/metastatic NSCLC with EGFR exon 20 insertions after platinum","from":"sunvozertinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Tafasitamab approved in US","note":"R/R follicular lymphoma with lenalidomide and rituximab","from":"tafasitamab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Taletrectinib approved in CN","note":"ROS1-positive NSCLC","from":"taletrectinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Taletrectinib approved in US","note":"Locally advanced or metastatic ROS1-positive NSCLC","from":"taletrectinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Tarlatamab approved in England (NICE)","note":"Extensive-stage small-cell lung cancer progressing after two or more lines of treatment including platinum-based chemotherapy: not recommended.","from":"tarlatamab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Telisotuzumab vedotin approved in US","note":"c-MET-high non-squamous NSCLC, previously treated (accelerated)","from":"telisotuzumab-vedotin","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Tislelizumab approved in US","note":"First-line ESCC, PD-L1 ≥1%, with platinum chemotherapy","from":"tislelizumab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Tisotumab vedotin approved in EU","note":"Recurrent/metastatic cervical after systemic therapy; 28 Mar 2025","from":"tisotumab-vedotin","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Trastuzumab deruxtecan approved in US","note":"HER2-low/ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Trastuzumab rezetecan approved in China","note":"HER2-mutant NSCLC after ≥1 systemic therapy (May 2025)","from":"trastuzumab-rezetecan","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Treosulfan approved in US","note":"Preparative regimen for allogeneic HSCT in AML/MDS with fludarabine","from":"treosulfan","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Vimseltinib approved in EU","note":"Symptomatic TGCT where surgery has been exhausted or would cause unacceptable morbidity; 17 Sep 2025","from":"vimseltinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Vimseltinib approved in US","note":"Symptomatic tenosynovial giant cell tumour where surgery would worsen function or cause severe morbidity","from":"vimseltinib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Vorasidenib approved in EU","note":"Grade 2 IDH-mutant glioma ≥12 yrs; 17 Sep 2025","from":"vorasidenib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Zanidatamab approved in EU","note":"HER2+ biliary tract after ≥1 line; 27 Jun 2025 (conditional). Conditional marketing authorisation","from":"zanidatamab","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Ziftomenib approved in US","note":"Relapsed/refractory NPM1-mutated AML with no satisfactory alternative","from":"ziftomenib","refs":[]},{"group":"approval","date":"2025","precision":"year","title":"Zongertinib approved in US","note":"HER2-mutant NSCLC, previously treated (accelerated)","from":"zongertinib","refs":[]},{"group":"company","date":"2025","precision":"year","title":"Bulsara Bioworks founded","note":"San Francisco, CA","from":"bulsara-bioworks","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Allotera Therapeutics (formerly Wugen): Series C","note":"$115m. Series C announced in late 2025 as stated in the July 2026 release","from":"allotera-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Ambagon Therapeutics: Form D offering","note":"$5m. Total sold of a 12 million US dollar offering per Form D filed February 2025; issuer address given as Eindhoven","from":"ambagon-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"ARTBIO: Series B","note":"$132m. Endpoints reports a USD 132 million raise in July 2025; the Series B label comes from the PR Newswire headline seen in search results, not from a fetched page","from":"artbio","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Ataraxis AI: Series A","note":"$20m. Led by AIX Ventures, March 2025.","from":"ataraxis-ai","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Blueprint Medicines: Acquisition","note":"$9.1bn. 129 US dollars per share in cash (equity value about 9.1 billion) plus a contingent value right worth up to 6 US dollars per share for BLU-808 milestones; tender offer comp...","from":"blueprint-medicines","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"BridgeBio Oncology Therapeutics: IPO","note":"$382m. Nasdaq listing via merger with Helix Acquisition Corp. II on 11 August 2025; about 261 million US dollar PIPE led by Cormorant plus about 120 million from the trust, roughly...","from":"bridgebio-oncology-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Callio Therapeutics: Series A","note":"$187m","from":"callio-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Capstan Therapeutics: Acquisition","note":"$2.1bn. AbbVie paid cash consideration of $2.1 billion ($1.9 billion net of cash acquired); completed August 2025","from":"capstan-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"CARGO Therapeutics: Acquisition","note":"$4.379 in cash per share plus a contingent value right; tender offer completed 18 August 2025","from":"cargo-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Cyted Health: Series B","note":"$44m. First close, August 2025; led by EQT Life Sciences with co-leads Advent Life Sciences and British Business Bank.","from":"cyted-health","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Deep 6 AI: Acquisition","note":"Acquired by Tempus AI on 11 March 2025; Deep 6 specific consideration not broken out in the 10-Q","from":"deep-6-ai","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Evergreen Theragnostics: Acquisition","note":"$250m. USD 250 million upfront plus up to USD 752.5 million in milestones; all-cash, announced 28 January 2025","from":"evergreen-theragnostics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Halda Therapeutics: Acquisition","note":"$3.0bn. 3.05 billion US dollars in cash; completion announced 29 December 2025","from":"halda-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"IGM Biosciences: Acquisition","note":"$1.247 in cash per share plus a contingent value right; agreement 1 July 2025, merger completed 14 August 2025","from":"igm-biosciences","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Imagene AI: Series B","note":"$23m. Led by Larry Ellison with Aguras Pathology Investments, July 2025; total funding $45 million. Source is the company release distributed via Newswire.com.","from":"imagene-ai","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Indapta Therapeutics: Form D offering","note":"$51m. Amount sold at filing of a $51.6 million offering, first sale 24 September 2025","from":"indapta-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"OncoHost: Grant","note":"$3m. EUR 2.5 million EIC Transition Programme grant, reported by the company as USD 2.8 million","from":"oncohost","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Orum Therapeutics: IPO","note":"KOSDAQ listing, 2,500,000 shares at KRW 20,000, gross proceeds about KRW 50 billion; trading from 14 February 2025 under code 475830","from":"orum-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Orum Therapeutics: Series C","note":"$100m. Post-IPO convertible preferred stock investment of KRW 145 billion (approximately USD 100 million) led by KB Investment; the company does not use a series letter","from":"orum-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Outcomes4Me: Series B","note":"$21m. Round not named by the company; labelled Series B here because it followed the 2021 Series A. Led by Salica Investments; total raised to date USD 38 million","from":"outcomes4me","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Owlstone Medical: Grant","note":"$49m. ARPA-H POSEIDON award of up to $49.1 million for at-home multi-cancer early detection tests, October 2025.","from":"owlstone-medical","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Owlstone Medical: Series E","note":"$27m. First close of about $27 million (approximately GBP 22 million) led by Ventura Capital, January 2025.","from":"owlstone-medical","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Pathos AI: Series D","note":"$365m. Post-money valuation about $1.6 billion, May 2025; investors not named in the release.","from":"pathos-ai","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Plexium: Form D offering","note":"$60m. Total sold per Form D filed August 2025; first sale July 2025","from":"plexium","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Poseida Therapeutics: Acquisition","note":"$1.5bn. $9.00 per share in cash (about $1.0 billion equity value) plus a contingent value right of up to $4.00 per share, total deal value up to about $1.5 billion; announced 26 No...","from":"poseida-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Scorpion Therapeutics: Acquisition","note":"Lilly's Q1 2025 results attribute most of a 1.57 billion US dollar acquired in-process R&D charge to the acquisition of Scorpion's PI3K-alpha inhibitor programme STX-478; headline...","from":"scorpion-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Strand Therapeutics: Series B","note":"$153m","from":"strand-therapeutics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Thyme Care: Series D","note":"$97m. Brought total raised to USD 275 million","from":"thyme-care","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Transgene: Crossover","note":"Public follow-on fundraising of about EUR 105 million (private placement plus PrimaryBid retail offering at EUR 1.02 per share), plus a EUR 39.3 million reserved capital increase f...","from":"transgene","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Treeline Biosciences: Form D offering","note":"$200m. Total sold of a 250 million US dollar offering per Form D filed September 2025","from":"treeline-biosciences","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Trial Library: Series A","note":"$10m. Co-led by NEXT Ventures and SemperVirens; total raised USD 17.6 million","from":"trial-library","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Triana Biomedicines: Series B","note":"$120m. Oversubscribed; co-led by Ascenta Capital and Bessemer Venture Partners; closed December 2025","from":"triana-biomedicines","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Turnstone Biologics: Acquisition","note":"$0.34 in cash per share plus a contingent value right; agreement 27 June 2025, merger completed 11 August 2025","from":"turnstone-biologics","refs":[]},{"group":"funding","date":"2025","precision":"year","title":"Vergent Bioscience: Form D offering","note":"$19m. Equity offering of up to USD 31.96 million, first sale 7 October 2025, USD 18.67 million sold at filing","from":"vergent-bioscience","refs":[]},{"group":"history","date":"2025","precision":"year","title":"AALL1731: blinatumomab added to chemotherapy lifts three-year disease-free survival to 96 percent","note":"Standard-risk B-cell acute lymphoblastic leukaemia in children","from":"all-paediatric-standard-risk","refs":["aall1731","paper-aall1731-blinatumomab-children-nejm-2025"]},{"group":"history","date":"2025","precision":"year","title":"AMPLIFY: acalabrutinib-venetoclax fixed duration in fit patients","note":"Chronic lymphocytic leukaemia, first treatment","from":"cll-treatment-naive","refs":["amplify","acalabrutinib","venetoclax"]},{"group":"history","date":"2025","precision":"year","title":"Analysis shows a large share of appendiceal cancers now arise in adults under 50","note":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","from":"appendiceal-adenocarcinoma","refs":[]},{"group":"history","date":"2025","precision":"year","title":"ArteraAI Prostate: first predictive AI pathology test","note":"Localised prostate cancer, intermediate risk","from":"prostate-intermediate-risk","refs":["artera-ai-prostate"]},{"group":"history","date":"2025","precision":"year","title":"ASCENT-03, ASCENT-04 and TROPION-Breast02 positive in the first line","note":"Metastatic triple-negative breast cancer","from":"tnbc-metastatic","refs":["ascent-03","ascent-04","tropion-breast02"]},{"group":"history","date":"2025","precision":"year","title":"At-home HPV self-test approved in the US; single-dose schedules adopted by 60+ countries","note":"Cervical cancer","from":"cervical","refs":["hpv-testing","gardasil-9"]},{"group":"history","date":"2025","precision":"year","title":"ATOMIC: adjuvant atezolizumab for dMMR stage III; sotorasib + panitumumab approved; CHALLENGE exercise trial","note":"Colorectal cancer","from":"colorectal","refs":["atomic","codebreak-300","exercise-oncology"]},{"group":"history","date":"2025","precision":"year","title":"Avutometinib plus defactinib approved for KRAS-mutant disease","note":"Low-grade serous ovarian cancer","from":"low-grade-serous-ovarian-cancer","refs":["avutometinib-defactinib"]},{"group":"history","date":"2025","precision":"year","title":"Beamion LUNG-1: zongertinib approved, the first oral HER2 inhibitor for lung cancer","note":"HER2-mutant non-small-cell lung cancer","from":"her2-mutant-nsclc","refs":["beamion-lung-1","zongertinib","john-heymach","boehringer-ingelheim"]},{"group":"history","date":"2025","precision":"year","title":"Belzutifan approved for advanced pheochromocytoma and paraganglioma","note":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","from":"hereditary-ppgl","refs":["belzutifan","nct04924075"]},{"group":"history","date":"2025","precision":"year","title":"Belzutifan approved for advanced pheochromocytoma and paraganglioma","note":"Metastatic pheochromocytoma and paraganglioma","from":"metastatic-ppgl","refs":["belzutifan","nct04924075"]},{"group":"history","date":"2025","precision":"year","title":"Belzutifan approved for PPGL","note":"Pheochromocytoma and paraganglioma (PPGL). FDA, 14 May 2025, LITESPARK-015 cohort A1; first oral therapy for the disease.","from":"pheochromocytoma-paraganglioma","refs":["belzutifan"]},{"group":"history","date":"2025","precision":"year","title":"BREAKWATER overall survival 30.3 versus 15.1 months","note":"BRAF V600E-mutant colorectal cancer","from":"braf-v600e-colorectal","refs":["breakwater","scott-kopetz","elena-elez"]},{"group":"history","date":"2025","precision":"year","title":"C-POST establishes adjuvant immunotherapy","note":"Cutaneous squamous cell carcinoma. 415 patients randomised after surgery and radiotherapy; 24-month disease-free survival 87.1 against 64.1 per cent, hazard ratio 0.32.","from":"cutaneous-scc","refs":["c-post"]},{"group":"history","date":"2025","precision":"year","title":"C-POST: adjuvant cemiplimab cuts recurrence after surgery and radiotherapy","note":"Advanced cutaneous squamous cell carcinoma","from":"advanced-cutaneous-scc","refs":["cemiplimab"]},{"group":"history","date":"2025","precision":"year","title":"C-POST: adjuvant cemiplimab reduces recurrence","note":"Cutaneous squamous cell carcinoma","from":"cutaneous-scc","refs":["cemiplimab"]},{"group":"history","date":"2025","precision":"year","title":"C-POST: the first drug shown to stop high-risk skin squamous cancer coming back","note":"Skin cancer (all types). 415 patients randomised after surgery and radiotherapy; 24-month disease-free survival 87.1 against 64.1 per cent with adjuvant cemiplimab.","from":"skin-cancer","refs":["c-post"]},{"group":"history","date":"2025","precision":"year","title":"Cabozantinib approved (March); COMPETE positive (ENETS, Lancet); AlphaMedix phase 2 meets all endpoints (October)","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["cabozantinib","compete","alphamedix-02"]},{"group":"history","date":"2025","precision":"year","title":"Cabozantinib approved for previously treated neuroendocrine tumours including lung; ESMO subgroup analysis","note":"Lung neuroendocrine tumours (typical and atypical carcinoid)","from":"lung-net","refs":["cabozantinib","cabinet"]},{"group":"history","date":"2025","precision":"year","title":"Cabozantinib approved for previously treated neuroendocrine tumours; COMPETE published","note":"Small intestinal neuroendocrine tumours","from":"small-intestinal-net","refs":["cabozantinib","compete"]},{"group":"history","date":"2025","precision":"year","title":"Cabozantinib approved; COMPETE published","note":"Pancreatic neuroendocrine tumours","from":"pancreatic-net","refs":["cabozantinib","compete"]},{"group":"history","date":"2025","precision":"year","title":"CheckMate 067 ten-year results: 43 percent alive on the combination","note":"Advanced melanoma (unresectable stage III and stage IV)","from":"advanced-melanoma","refs":["checkmate-067"]},{"group":"history","date":"2025","precision":"year","title":"CheckMate 743 five-year data: 14% vs 6% alive","note":"Mesothelioma","from":"mesothelioma","refs":["checkmate-743"]},{"group":"history","date":"2025","precision":"year","title":"CheckMate 9DW approval (nivolumab + ipilimumab); second FDA CRL for camrelizumab-rivoceranib","note":"Hepatocellular carcinoma","from":"hcc","refs":["checkmate-9dw","camrelizumab-rivoceranib"]},{"group":"history","date":"2025","precision":"year","title":"CheckMate 9DW: nivolumab plus ipilimumab beats lenvatinib or sorafenib","note":"Advanced hepatocellular carcinoma (BCLC C)","from":"hcc-advanced","refs":["checkmate-9dw","nivolumab","ipilimumab"]},{"group":"history","date":"2025","precision":"year","title":"Colibactin mutational signature found enriched in early-onset tumours (Nature)","note":"Early-onset colorectal cancer (under 50)","from":"early-onset-colorectal","refs":["colorectal-screening"]},{"group":"history","date":"2025","precision":"year","title":"Daratumumab approved for high-risk smouldering myeloma in the United States","note":"Smouldering multiple myeloma","from":"smouldering-myeloma","refs":["daratumumab"]},{"group":"history","date":"2025","precision":"year","title":"DeLLphi-304 OS benefit and full approval of tarlatamab; IMforte maintenance approved","note":"Small-cell lung cancer","from":"sclc","refs":["dellphi-304","imforte","lurbinectedin"]},{"group":"history","date":"2025","precision":"year","title":"DeLLphi-304: tarlatamab lengthens survival after relapse; IMforte: lurbinectedin maintenance approved","note":"Extensive-stage small-cell lung cancer","from":"extensive-stage-sclc","refs":["dellphi-304","tarlatamab","imforte","lurbinectedin"]},{"group":"history","date":"2025","precision":"year","title":"DESTINY-Breast05 and DESTINY-Breast11","note":"Early HER2-positive breast cancer","from":"her2-positive-early-breast-cancer","refs":["destiny-breast05","destiny-breast11","trastuzumab-deruxtecan"]},{"group":"history","date":"2025","precision":"year","title":"DESTINY-Breast09 first-line approval; DESTINY-Breast05 and HER2CLIMB-05 positive; trastuzumab rezetecan approved (China, NSCLC)","note":"HER2-positive breast cancer","from":"breast-her2-positive","refs":["destiny-breast09","destiny-breast05","her2climb-05","trastuzumab-rezetecan"]},{"group":"history","date":"2025","precision":"year","title":"DESTINY-Gastric04: trastuzumab deruxtecan beats ramucirumab-paclitaxel in the second line","note":"HER2-positive gastric cancer","from":"gastric-her2-positive","refs":["destiny-gastric04"]},{"group":"history","date":"2025","precision":"year","title":"Dordaviprone approved","note":"Diffuse midline glioma, H3 K27-altered (including DIPG). FDA accelerated approval on 6 August 2025 for progressive H3 K27M-mutant diffuse midline glioma, the first systemic therapy...","from":"dipg-dmg","refs":["dordaviprone"]},{"group":"history","date":"2025","precision":"year","title":"Dordaviprone approved for H3 K27M diffuse midline glioma","note":"Glioma & glioblastoma. 6 August 2025; first systemic therapy for the disease.","from":"glioblastoma","refs":["dordaviprone"]},{"group":"history","date":"2025","precision":"year","title":"ECLIPSE: 177Lu-PSMA-I&T meets its endpoint","note":"Metastatic castration-resistant prostate cancer","from":"prostate-mcrpc","refs":["eclipse-psma"]},{"group":"history","date":"2025","precision":"year","title":"EMERALD-1 and LEAP-012: systemic therapy plus TACE delays progression","note":"Intermediate hepatocellular carcinoma (BCLC B)","from":"hcc-intermediate","refs":["emerald-1","leap-012"]},{"group":"history","date":"2025","precision":"year","title":"FDA approves sotorasib with panitumumab","note":"KRAS G12C-mutant colorectal cancer","from":"kras-g12c-colorectal","refs":["sotorasib","panitumumab"]},{"group":"history","date":"2025","precision":"year","title":"FDA restricts first-line PD-1 antibodies to PD-L1 CPS 1 or above; MATTERHORN positive with durvalumab and FLOT","note":"PD-L1-high gastric cancer","from":"gastric-pdl1-high","refs":["matterhorn","durvalumab"]},{"group":"history","date":"2025","precision":"year","title":"First LGSOC therapy (avutometinib + defactinib); ROSELLA and KEYNOTE-B96 positive","note":"Ovarian cancer","from":"ovarian","refs":["avutometinib-defactinib","ramp-201","rosella","keynote-b96"]},{"group":"history","date":"2025","precision":"year","title":"First MET ADC (telisotuzumab vedotin); Dato-DXd in EGFR-mutant disease; MARIPOSA OS benefit; HER3-DXd BLA withdrawn; zongertinib and sevabertinib approved","note":"Non-small-cell lung cancer","from":"nsclc","refs":["telisotuzumab-vedotin","datopotamab-deruxtecan","tropion-lung05","herthena-lung02"]},{"group":"history","date":"2025","precision":"year","title":"First-line ADC era begins","note":"Triple-negative breast cancer (TNBC). ASCENT-03, ASCENT-04, and TROPION-Breast02 all positive; TROPION-Breast02 shows OS benefit.","from":"tnbc","refs":["ascent-03","ascent-04","tropion-breast02"]},{"group":"history","date":"2025","precision":"year","title":"HER2CLIMB-05: tucatinib in first-line maintenance","note":"HER2-positive breast cancer with brain metastases","from":"her2-positive-breast-brain-metastases","refs":["her2climb-05"]},{"group":"history","date":"2025","precision":"year","title":"IMbrave050 update: the recurrence-free survival benefit is not sustained","note":"Early hepatocellular carcinoma (BCLC 0 and A)","from":"hcc-early","refs":["imbrave050"]},{"group":"history","date":"2025","precision":"year","title":"Imlunestrant approved; INAVO120 OS benefit; T-DXd in HER2-ultralow; evERA and lidERA positive","note":"HR-positive / HER2-negative breast cancer","from":"breast-hr-positive","refs":["imlunestrant","ember-3","destiny-breast06","evera"]},{"group":"history","date":"2025","precision":"year","title":"Indian and Chilean landscapes published","note":"Gallbladder cancer. 376 Indian patients (Suryavanshi et al.) and 56 Chilean tumours (Erices et al.) give the high-incidence regions their own frequencies.","from":"gallbladder","refs":["paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025","paper-erices-chilean-gallbladder-landscape-front-oncol-2025"]},{"group":"history","date":"2025","precision":"year","title":"IoN confirms omission of radioiodine in low-risk disease (Lancet)","note":"Thyroid cancer","from":"thyroid","refs":["ion-trial"]},{"group":"history","date":"2025","precision":"year","title":"KEYNOTE-689 approval and NIVOPOSTOP: immunotherapy around surgery","note":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","from":"hpv-negative-head-and-neck-cancer","refs":["keynote-689","nivopostop"]},{"group":"history","date":"2025","precision":"year","title":"KEYNOTE-689 perioperative pembrolizumab approved; NRG-HN005 de-escalation fails; petosemtamab and ficerafusp alfa phase 3 trials","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["keynote-689","nrg-hn002-hn005","liger-hn1","fortifi-hn01"]},{"group":"history","date":"2025","precision":"year","title":"KEYNOTE-689: neoadjuvant IO","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":[]},{"group":"history","date":"2025","precision":"year","title":"KEYNOTE-B96: pembrolizumab with paclitaxel extends survival in PD-L1-positive disease","note":"Platinum-resistant ovarian cancer","from":"platinum-resistant-ovarian-cancer","refs":["keynote-b96","pembrolizumab"]},{"group":"history","date":"2025","precision":"year","title":"lidERA: adjuvant giredestrant improves invasive disease-free survival","note":"High-risk early HR-positive breast cancer","from":"hr-positive-early-high-risk","refs":["lidera","giredestrant"]},{"group":"history","date":"2025","precision":"year","title":"Linvoseltamab approved; belantamab re-approved; IMROZ/CEPHEUS labels; iMMagine-1 reports 97% ORR","note":"Multiple myeloma","from":"multiple-myeloma","refs":["linvoseltamab","linker-mm1","belantamab-mafodotin","imroz"]},{"group":"history","date":"2025","precision":"year","title":"Linvoseltamab approved; belantamab returns after DREAMM-7 and DREAMM-8; MajesTEC-3 reads out","note":"Relapsed or refractory multiple myeloma","from":"myeloma-relapsed-refractory","refs":["linvoseltamab","belantamab-mafodotin","dreamm-7","majestec-3"]},{"group":"history","date":"2025","precision":"year","title":"Long-term GD2 CAR-T follow-up (Nature Medicine); naxitamab primary-refractory phase 2 (75% CR); eflornithine EU filing","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":["gd2-cart01","naxitamab","eflornithine"]},{"group":"history","date":"2025","precision":"year","title":"MATTERHORN: perioperative durvalumab approved; DESTINY-Gastric04 phase 3; satri-cel CAR-T approved in China; FORTITUDE-101 mixed; CheckMate 649 five-year data","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["matterhorn","destiny-gastric04","satricabtagene-autoleucel","fortitude-101"]},{"group":"history","date":"2025","precision":"year","title":"Menin inhibitors reach NPM1-mutated AML","note":"Acute myeloid leukaemia. Revumenib NPM1 label (October) and ziftomenib approval (13 November, KOMET-001).","from":"aml","refs":["ziftomenib","komet-001","revumenib"]},{"group":"history","date":"2025","precision":"year","title":"Mirdametinib approved for NF1 plexiform neurofibromas in adults and children","note":"Malignant peripheral nerve sheath tumour (MPNST)","from":"malignant-peripheral-nerve-sheath-tumour","refs":["mirdametinib"]},{"group":"history","date":"2025","precision":"year","title":"NIAGARA perioperative durvalumab (March); Inlexzo/TAR-200 (September); EV-303 perioperative EV + pembrolizumab (November); EV-304 positive (December)","note":"Bladder & urothelial cancer","from":"urothelial","refs":["niagara","tar-200","ev-303","ev-304"]},{"group":"history","date":"2025","precision":"year","title":"Nivolumab-ipilimumab approved first line; ATOMIC shows adjuvant atezolizumab helps stage III disease","note":"Mismatch-repair deficient (MSI-high) colorectal cancer","from":"msi-high-colorectal","refs":["nivolumab","ipilimumab","atomic"]},{"group":"history","date":"2025","precision":"year","title":"NIVOPOSTOP: nivolumab after surgery for high-risk disease","note":"Hypopharyngeal cancer","from":"hypopharyngeal-cancer","refs":["nivopostop"]},{"group":"history","date":"2025","precision":"year","title":"NRG-HN005 closed: de-escalated chemoradiation arms worse","note":"HPV-positive oropharyngeal cancer","from":"hpv-positive-oropharyngeal-cancer","refs":["nrg-hn002-hn005"]},{"group":"history","date":"2025","precision":"year","title":"PANOVA-3 positive; daraxonrasib phase 1/2 OS ~14.5 months","note":"Pancreatic ductal adenocarcinoma. Tumour treating fields with gemcitabine and nab-paclitaxel: 16.2 against 14.2 months in 571 patients with locally advanced disease.","from":"pancreatic","refs":["panova-3","daraxonrasib","paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025"]},{"group":"history","date":"2025","precision":"year","title":"PANOVA-3: tumour treating fields with gemcitabine plus nab-paclitaxel lengthen survival","note":"Locally advanced unresectable pancreatic ductal adenocarcinoma","from":"locally-advanced-pdac","refs":["panova-3","ttfields","gemcitabine-nab-paclitaxel"]},{"group":"history","date":"2025","precision":"year","title":"Penpulimab approved (FDA)","note":"Nasopharyngeal carcinoma","from":"nasopharyngeal","refs":["penpulimab"]},{"group":"history","date":"2025","precision":"year","title":"Penpulimab with gemcitabine-cisplatin approved in the United States","note":"Recurrent and metastatic nasopharyngeal carcinoma","from":"recurrent-metastatic-nasopharyngeal-carcinoma","refs":["penpulimab","nct04974398"]},{"group":"history","date":"2025","precision":"year","title":"Petosemtamab with pembrolizumab: phase 2 responses in about six in ten; phase 3 under way","note":"Recurrent or metastatic head and neck squamous cell carcinoma","from":"recurrent-metastatic-hnscc","refs":["petosemtamab","liger-hn1"]},{"group":"history","date":"2025","precision":"year","title":"Pirtobrutinib traditional approval; sonrotoclax approved in China","note":"Chronic lymphocytic leukaemia. BRUIN CLL-321 confirms benefit after covalent BTKi (3 December); next-generation BCL-2 inhibitor reaches patients.","from":"cll","refs":["pirtobrutinib","bruin-cll-321","sonrotoclax"]},{"group":"history","date":"2025","precision":"year","title":"Pluvicto pre-chemotherapy (PSMAfore); ArteraAI Prostate FDA-authorised; PSMAddition positive; ECLIPSE positive; masofaniten discontinued","note":"Prostate cancer","from":"prostate","refs":["psmafore","artera-ai-prostate","psmaddition","eclipse-psma"]},{"group":"history","date":"2025","precision":"year","title":"POD1UM-201: a third PD-1 antibody with three-year follow-up","note":"Merkel cell carcinoma. Objective response 54.5 per cent in 101 chemotherapy-naive patients, median progression-free survival 16.0 months and 63 per cent alive at three years.","from":"merkel-cell-carcinoma","refs":["pod1um-201"]},{"group":"history","date":"2025","precision":"year","title":"POD1UM-303 published; retifanlimab with carboplatin and paclitaxel approved in the United States","note":"Metastatic and recurrent anal squamous cell carcinoma","from":"metastatic-anal-cancer","refs":["retifanlimab","carboplatin","paclitaxel"]},{"group":"history","date":"2025","precision":"year","title":"PREOPANC-2 leaves the resectable question open; vaccine T cells last years","note":"Pancreatic ductal adenocarcinoma. Neoadjuvant FOLFIRINOX 21.9 versus 21.3 months against gemcitabine chemoradiotherapy.","from":"pancreatic","refs":["paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025","paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease"]},{"group":"history","date":"2025","precision":"year","title":"RELATIVITY-098 adjuvant LAG-3 negative; CheckMate 067 ten-year survival ~50%","note":"Melanoma","from":"melanoma","refs":["relativity-098","checkmate-067"]},{"group":"history","date":"2025","precision":"year","title":"REMS removed for CAR-T; menin inhibitor combinations enter ALL trials","note":"Acute lymphoblastic leukaemia. FDA lifts REMS for approved CAR-T products; ziftomenib and revumenib studied in KMT2Ar ALL.","from":"all-leukemia","refs":["tisagenlecleucel","ziftomenib"]},{"group":"history","date":"2025","precision":"year","title":"Rina-S Breakthrough designation in endometrial cancer","note":"Endometrial cancer","from":"endometrial","refs":["rinatabart-sesutecan","rainfol-01"]},{"group":"history","date":"2025","precision":"year","title":"ROSELLA: relacorilant with nab-paclitaxel extends survival, 16.0 versus 11.9 months","note":"Platinum-resistant ovarian cancer","from":"platinum-resistant-ovarian-cancer","refs":["rosella","relacorilant"]},{"group":"history","date":"2025","precision":"year","title":"Satri-cel CAR-T approved in China","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["satricabtagene-autoleucel"]},{"group":"history","date":"2025","precision":"year","title":"SERENA-6: switch to camizestrant on circulating tumour DNA; imlunestrant approved (EMBER-3)","note":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","from":"hr-positive-metastatic-post-cdk46","refs":["serena-6","camizestrant","ember-3","imlunestrant"]},{"group":"history","date":"2025","precision":"year","title":"SUNMO positive (mosun-pola); FDA rejects STARGLO indication over applicability; POLARIX 5-year data","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["sunmo","starglo","polarix"]},{"group":"history","date":"2025","precision":"year","title":"Sunvozertinib approved for exon 20 insertions; datopotamab deruxtecan approved after EGFR inhibitor and chemotherapy","note":"EGFR-mutated non-small-cell lung cancer","from":"egfr-mutant-nsclc","refs":["sunvozertinib","datopotamab-deruxtecan","tropion-lung05"]},{"group":"history","date":"2025","precision":"year","title":"Taletrectinib approved after TRUST-I and TRUST-II","note":"ROS1-positive non-small-cell lung cancer","from":"ros1-positive-nsclc","refs":["taletrectinib","nct04395677"]},{"group":"history","date":"2025","precision":"year","title":"Telisotuzumab vedotin approved; SACHI: osimertinib plus savolitinib for MET-amplified resistance","note":"MET exon 14 and MET-amplified non-small-cell lung cancer","from":"met-altered-nsclc","refs":["telisotuzumab-vedotin","savolitinib","osimertinib"]},{"group":"history","date":"2025","precision":"year","title":"The de-escalation year: INSEMA, NSABP B-51 and SUPREMO","note":"Breast cancer (all types). Axillary surgery omitted in 4,858 patients, regional nodal irradiation dropped after a complete nodal response, and no survival gain from chest-wall radi...","from":"breast-cancer","refs":["insema","nsabp-b51","supremo"]},{"group":"history","date":"2025","precision":"year","title":"Tislelizumab first-line ESCC approval; CheckMate 577 final OS not significant; DESTINY-Gastric04 for HER2+ GEJ","note":"Oesophageal cancer","from":"esophageal","refs":["tislelizumab","checkmate-577","destiny-gastric04"]},{"group":"history","date":"2025","precision":"year","title":"TNM 9 comes into force","note":"Lung cancer (all types). From 1 January 2025 lung cancer is staged by the ninth edition: the T descriptors unchanged, N2 split into N2a and N2b by the number of mediastinal station...","from":"lung-cancer","refs":["tnm-9-lung-cancer","tnm-staging"]},{"group":"history","date":"2025","precision":"year","title":"TOPAZ-1 three-year survival update; FIRST-308 doses first US patient","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["topaz-1","first-308"]},{"group":"history","date":"2025","precision":"year","title":"TOPAZ-1 three-year update; ctDNA residual disease shown prognostic after biliary resection","note":"Gallbladder cancer. 36-month survival 14.6 vs 6.9 percent with durvalumab. Residual disease hazard ratios of 26 (2025) and 15.86 (2026) in two cohorts.","from":"gallbladder","refs":["paper-topaz-1-three-year-survival-j-hepatol-2025","paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025","paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026"]},{"group":"history","date":"2025","precision":"year","title":"VERIFY: a hepcidin mimetic replaces phlebotomy","note":"Polycythaemia vera (PV). Rusfertide added to standard care made most patients phlebotomy-free over weeks 20 to 32.","from":"polycythaemia-vera","refs":["verify","rusfertide"]},{"group":"history","date":"2025","precision":"year","title":"Vimseltinib approved","note":"Tenosynovial giant cell tumour (TGCT). FDA approval 14 February 2025 for symptomatic TGCT where surgery would worsen function.","from":"tenosynovial-giant-cell-tumour","refs":["vimseltinib"]},{"group":"history","date":"2025","precision":"year","title":"Vimseltinib approved (14 Feb); lete-cel and Tecelra transferred to US WorldMeds","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["vimseltinib","letetresgene-autoleucel","us-worldmeds"]},{"group":"history","date":"2025","precision":"year","title":"Ziftomenib and revumenib approved for relapsed NPM1-mutated AML","note":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","from":"aml-npm1-kmt2a","refs":["komet-001","ziftomenib","revumenib"]},{"group":"law","date":"2025","precision":"year","title":"European Health Data Space Regulation (EU) 2025/327","note":"European Union, regulation.","from":"european-health-data-space","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2...","note":"Hughes BGM, Guminski A, Bowyer S, et al. Journal of the American Academy of Dermatology.","from":"paper-empower-cscc-1-j-am-acad-dermatol-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"A vision-language foundation model for precision oncology","note":"Xiang J, Wang X, Zhang X, et al. Nature.","from":"paper-xiang-nature","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase...","note":"Smith M, Piulats J, Todenhöfer T, et al. The Lancet Oncology.","from":"paper-nct03706365-lancet-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Access to timely cancer treatment initiation in India: extent, determinants and trends","note":"Halder P, Dixit J, Gupta N, et al. The Lancet regional health. Southeast Asia.","from":"paper-halder-lancet-reg-health-southeast-asia","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial","note":"Hwang ES, Hyslop T, Lynch T, et al. JAMA.","from":"paper-comet-dcis-jama-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","note":"Long GV, Garnett-Benson C, Dolfi S, et al. Nature Medicine.","from":"paper-relativity-098-nat-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","note":"Brown JR, Seymour JF, Jurczak W, et al. New England Journal of Medicine.","from":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma","note":"Dimopoulos MA, Voorhees PM, Schjesvold F, et al. New England Journal of Medicine.","from":"paper-aquila-daratumumab-smouldering-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (...","note":"Anderson C, Lee CM, Kelley JR, et al. eClinicalMedicine.","from":"paper-roman-anderson-eclinicalmedicine-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer","note":"Heymach JV, Ruiter G, Ahn MJ, et al. New England Journal of Medicine.","from":"paper-beamion-lung-1-zongertinib-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","note":"Benson AB, D'Angelica MI, Abrams T, et al. Journal of the National Comprehensive Cancer Network.","from":"paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","note":"Wang J, Zhang Q, Li H, et al. Nature Communications.","from":"paper-nct05077449-nat-commun-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","note":"Elez E, Yoshino T, Shen L, et al. New England Journal of Medicine.","from":"paper-breakwater-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma","note":"Rischin D, Porceddu S, Day F, et al. New England Journal of Medicine.","from":"paper-c-post-adjuvant-cemiplimab-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","note":"Chan JA, Geyer S, Zemla T, et al. New England Journal of Medicine.","from":"paper-cabinet-cabozantinib-nejm-2024","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","note":"Agarwal N, Azad AA, Carles J, et al. The Lancet Oncology.","from":"paper-nct04446117-lancet-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","note":"Usmani SZ, Facon T, Hungria V, et al. Nature Medicine.","from":"paper-cepheus-dara-vrd-natmed-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","note":"Courneya KS, Vardy JL, O'Callaghan CJ, et al. (Canadian Cancer Trials Group CO.21). New England Journal of Medicine.","from":"paper-challenge-exercise-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","note":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. New England Journal of Medicine.","from":"paper-checkmate-067-10-year-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer","note":"André T, Elez E, Lenz HJ, et al. The Lancet.","from":"paper-checkmate-8hw-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","note":"Gupta S, Rau RE, Kairalla JA, et al. New England Journal of Medicine.","from":"paper-aall1731-blinatumomab-children-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","note":"Tie J, Wang Y, Lo SN, et al. Nature Medicine.","from":"paper-dynamic-nat-med-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophagea...","note":"Qi C, Liu C, Peng Z, et al. The Lancet.","from":"paper-ct041-st-01-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer (PREEMPT CRC)","note":"Shaukat A, Burke CA, Chan AT, et al. JAMA.","from":"paper-preempt-crc-shaukat-jama-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"CLL12: ibrutinib in early-stage chronic lymphocytic leukaemia, a randomised placebo-controlled phase 3 trial","note":"Langerbeins P, Robrecht S, Nieper P, et al. Journal of Clinical Oncology.","from":"paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","note":"Peled N, Tufman A, Sequist LV, et al. ESMO Open.","from":"paper-nct04765059-esmo-open-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","note":"Sands J, Ahn MJ, Lisberg A, et al. Journal of Clinical Oncology.","from":"paper-tropion-lung05-j-clin-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection","note":"Yu J, He AR, Ouf M, et al. JCO Precision Oncology.","from":"paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer","note":"Laktionov K, Smolin A, Stroyakovskiy D, et al. European Journal of Cancer.","from":"paper-laktionov-prolgolimab-domajor-ejc-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial","note":"Hsiehchen D, Kainthla R, Kline H, et al. Nature Communications.","from":"paper-nct05724563-nat-commun-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","note":"Oh DY, He AR, Qin S, et al. Journal of Hepatology.","from":"paper-topaz-1-three-year-survival-j-hepatol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PE...","note":"Lu S, Wu L, Wang Q, et al. Journal of Thoracic Oncology.","from":"paper-nct03003962-j-thorac-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study","note":"Chen D, Le SB, Ghiaseddin AP, et al. Med (New York, N.Y.).","from":"paper-pembrolizumab-glioblastoma-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, mu...","note":"Paz-Ares L, Borghaei H, Liu SV, et al. The Lancet.","from":"paper-imforte-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising m...","note":"Shi Y, Wu L, Ji Y, et al. The Lancet. Respiratory medicine.","from":"paper-nct04143607-lancet-respir-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer","note":"Cardoso F, Parke S, Brennan DJ, et al. New England Journal of Medicine.","from":"paper-nct05587296-n-engl-j-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma","note":"Sangro B, Kudo M, Erinjeri JP, et al. The Lancet.","from":"paper-emerald-1-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","note":"Kopetz S, Yoshino T, Van Cutsem E, et al. Nature Medicine.","from":"paper-breakwater-nat-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","note":"Cho BC, Li W, Spira AI, et al. Journal of Thoracic Oncology.","from":"paper-nct06120140-j-thorac-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer","note":"Schram AM, Goto K, Kim DW, et al. New England Journal of Medicine.","from":"paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial","note":"Brody JD, Jørgensen J, Belada D, et al. Blood.","from":"paper-epcoritamab-dlbcl-blood-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1","note":"Darman L, Kaurich Q, Hassan MS, et al. International journal of molecular sciences.","from":"paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review","note":"Li Q, Vignali P, Tang D, et al. Cancers.","from":"paper-cd47-colorectal-cancers-basel-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HE...","note":"Jänne PA, Goto Y, Kubo T, et al. Journal of Thoracic Oncology.","from":"paper-destiny-lung02-j-thorac-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignanci...","note":"Kummar S, Razak AA, Laurie S, et al. Cancer research communications.","from":"paper-nct05199272-cancer-res-commun-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Es...","note":"Baldini C, Verlingue L, Goldschmidt V, et al. Journal of Clinical Oncology.","from":"paper-nct04561362-j-clin-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer","note":"Bidard FC, Mayer EL, Park YH, et al. New England Journal of Medicine.","from":"paper-serena-6-n-engl-j-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase I...","note":"Jänne PA, Wang BC, Cho BC, et al. Journal of Clinical Oncology.","from":"paper-nct04129502-j-clin-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","note":"Hong S, Wang Q, Cheng Y, et al. Nature Medicine.","from":"paper-nct05351788-nat-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with K...","note":"Ruan DY, Wu HX, Xu Y, et al. Signal transduction and targeted therapy.","from":"paper-nct04585035-signal-transduct-target-ther-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Genomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population","note":"Suryavanshi M, Ostwal V, Javle MM, et al. JCO Global Oncology.","from":"paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Geographic and age variations in mutational processes in colorectal cancer","note":"Díaz-Gay M, Dos Santos W, Moody S, et al. Nature.","from":"paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","note":"Shi Y, Fang J, Xing L, et al. Nature Medicine.","from":"paper-nct05009329-nat-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","note":"Zhou C, Chen J, Wu L, et al. The Lancet.","from":"paper-harmoni-2-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Hospital-based gallbladder cancer registry from a high-volume referral cancer centre in India: Insights into epidemiology and roadmap for enhancing cancer care","note":"Patkar S, Shah TM, Varty G, et al. Cancer Epidemiology.","from":"paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer","note":"Zhan J, Xue J, Wu L, et al. Journal of translational medicine.","from":"paper-nct05435248-j-transl-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy","note":"Wong MK, Milhem MM, Sacco JJ, et al. Journal of Clinical Oncology.","from":"paper-wong-ignyte-rp1-nivolumab-jco-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","note":"Jhaveri KL, Neven P, Casalnuovo ML, et al. New England Journal of Medicine.","from":"paper-ember-3-n-engl-j-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs.","note":"Demidov L, Samoylenko I, Kharkevich G, et al. European Journal of Cancer.","from":"paper-nct05732805-eur-j-cancer-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","note":"Powles T, Chang Y-H, Yamamoto Y, et al. New England Journal of Medicine.","from":"paper-imvigor011-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Ivermectin and gynecologic cancer: what's the data?","note":"Mujumdar V, Huang M, Smith LC, Musa F. Gynecologic Oncology Reports.","from":"paper-mujumdar-ivermectin-gynaecological-cancer-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?","note":"Patel Y, Chawla J, Parmar MS. Current Oncology Reports.","from":"paper-patel-ivermectin-cancer-curr-oncol-rep-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Ivermectin treatment for gynecologic cancers: hope versus hype","note":"Straughn JM. Gynecologic Oncology Reports.","from":"paper-straughn-ivermectin-hope-versus-hype-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a rand...","note":"Chen Z, Yang F, Jiang Z, et al. The Lancet.","from":"paper-nct05840016-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer","note":"Uppaluri R, Haddad RI, Tao Y, et al. New England Journal of Medicine.","from":"paper-keynote-689-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma","note":"Kudo M, Ren Z, Guo Y, et al. The Lancet.","from":"paper-leap-012-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung ca...","note":"Lu S, Yu Y, Zhou J, et al. Translational lung cancer research.","from":"paper-nct04270591-transl-lung-cancer-res-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer","note":"Martling A, Hed Myrberg I, Nilbert M, et al. New England Journal of Medicine.","from":"paper-alascca-n-engl-j-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"MATTERHORN: perioperative durvalumab with FLOT chemotherapy for resectable gastric and gastro-oesophageal junction cancer","note":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. New England Journal of Medicine.","from":"paper-matterhorn-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"National Cancer Grid initiative for electronic medical records, India","note":"Pramesh CS, Koita R, Sengar M, et al. Bulletin of the World Health Organization.","from":"paper-pramesh-bull-world-health-organ","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicen...","note":"Janssen QP, van Dam JL, van Bekkum ML, et al. The Lancet Oncology.","from":"paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","note":"Kähler KC, Hassel JC, Ziemer M, et al. Annals of Oncology.","from":"paper-nct02938299-ann-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Neoadjuvant treatment for incidental gallbladder cancer: A systematic review","note":"Varshney P, Baghmar S, Sirohi B, et al. Annals of Hepato-Biliary-Pancreatic Surgery.","from":"paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study","note":"Wang F, Chen G, Qiu M, et al. Cancer Cell.","from":"paper-nct05890742-cancer-cell-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","note":"Attard G, Agarwal N, Graff JN, et al. Nature Medicine.","from":"paper-nct04497844-nat-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial","note":"Gao B, Carlino MS, Michael M, et al. JAMA Oncology.","from":"paper-nct04969887-jama-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Nonoperative management of mismatch repair-deficient tumors","note":"Cercek A, Foote MB, Rousseau B, et al. New England Journal of Medicine.","from":"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Nucleotide Transformer: building and evaluating robust foundation models for human genomics","note":"Dalla-Torre H, Gonzalez L, Mendoza-Revilla J, et al. Nature methods.","from":"paper-dalla-torre-nat-methods","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial","note":"Ahn DH, Ridinger M, Cannon TL, et al. Journal of Clinical Oncology.","from":"paper-nct06106308-j-clin-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal G...","note":"Riess JW, de Langen AJ, Ponce S, et al. JCO Precision Oncology.","from":"paper-nct03944772-jco-precis-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer","note":"Jhaveri KL, Im SA, Saura C, et al. New England Journal of Medicine.","from":"paper-inavo120-n-engl-j-med-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","note":"Forde PM, Spicer JD, Provencio M, et al. New England Journal of Medicine.","from":"paper-checkmate-816-n-engl-j-med-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequentia...","note":"Wu YL, Wu L, Bi N, et al. Journal of hematology & oncology.","from":"paper-nct03706690-j-hematol-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER + /HER2 - breast cancer: a randomized phase 3 trial","note":"Cardoso F, O'Shaughnessy J, Liu Z, et al. Nature Medicine.","from":"paper-nct03725059-nat-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","note":"Mittendorf EA, Assaf ZJ, Harbeck N, et al. Nature Medicine.","from":"paper-impassion031-nat-med-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","note":"Cascone T, Bonanno L, Guisier F, et al. Nature Medicine.","from":"paper-nct05061550-nat-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a rando...","note":"Yue D, Wang W, Liu H, et al. The Lancet. Respiratory medicine.","from":"paper-nct04379635-lancet-respir-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer","note":"Lentz RW, Lang J, Pitts TM, et al. Cancer research communications.","from":"paper-cd47-colorectal-cancer-res-commun-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutati...","note":"Yang JC, Wang M, Doucet L, et al. Journal of Clinical Oncology.","from":"paper-nct03974022-j-clin-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma","note":"Chen W, Fu C, Fang B, et al. Experimental hematology & oncology.","from":"paper-chen-exp-hematol-oncol","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"POD1UM-303/InterAACT-2: retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic anal squamous cell carcinoma","note":"Rao S, Samalin-Scalzi E, Evesque L, et al. The Lancet.","from":"paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance","note":"Zhu Y, Solis Soto LM, Pant S, et al. Modern Pathology.","from":"paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation","note":"Linder J, Srivastava D, Yuan H, et al. Nature Genetics.","from":"paper-linder-nat-genet","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: Chec...","note":"Long GV, Tang H, Desai K, et al. Journal for ImmunoTherapy of Cancer.","from":"paper-checkmate-915-j-immunother-cancer-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report","note":"Spira AI, Paz-Ares L, Han JY, et al. Journal of Thoracic Oncology.","from":"paper-nct05663866-j-thorac-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer","note":"Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al. Journal of Clinical Oncology.","from":"paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma","note":"Iwamoto FM, Tanguturi SK, Nayak L, et al. Clinical Cancer Research.","from":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","note":"Nakagawa K, Garon EB, Seto T, et al. Journal of Thoracic Oncology.","from":"paper-nct02411448-j-thorac-oncol-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapi...","note":"Ouyang Q, Rodon J, Liang Y, et al. Journal of hematology & oncology.","from":"paper-nct04152499-j-hematol-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"RETRACTED: Fenbendazole as an anticancer agent? A case series of self-administration in three patients","note":"Makis W, Baghli I, Martinez P. Case Reports in Oncology.","from":"paper-makis-fenbendazole-case-series-retracted-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial","note":"Fasching PA, Stroyakovskiy D, Yardley DA, et al. JAMA Oncology.","from":"paper-natalee-jama-oncol-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","note":"Sethna Z, Guasp P, Reiche C, et al. Nature.","from":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer","note":"Olawaiye AB, Gladieff L, O'Malley DM, et al. The Lancet.","from":"paper-rosella-relacorilant-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","note":"Cortés J, Punie K, Barrios C, et al. New England Journal of Medicine.","from":"paper-ascent-03-n-engl-j-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","note":"Yin Y, Fan Y, Ouyang Q, et al. Nature Medicine.","from":"paper-nct05347134-nat-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification...","note":"de Marinis F, Kim TM, Bonanno L, et al. Annals of Oncology.","from":"paper-nct03778229-ann-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Scalable emulation of protein equilibrium ensembles with generative deep learning","note":"Lewis S, Hempel T, Jiménez-Luna J, et al. Science.","from":"paper-lewis-science","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, contr...","note":"Hernström V, Josefsson V, Sartor H, et al. The Lancet Digital Health.","from":"paper-masai-lancet-digit-health-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistan...","note":"Mehr S, Hauke R. Oncology and therapy.","from":"paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Sevabertinib in Advanced HER2 -Mutant Non-Small-Cell Lung Cancer","note":"Le X, Kim TM, Loong HH, et al. New England Journal of Medicine.","from":"paper-soho-01-n-engl-j-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Simulating 500 million years of evolution with a language model","note":"Hayes T, Rao R, Akin H, et al. Science.","from":"paper-hayes-science","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77...","note":"Felip E, Rojas CI, Schenker M, et al. Annals of Oncology.","from":"paper-nct05722015-ann-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","note":"Jacob JM, Daneshmand S, Necchi A, et al. Journal of Clinical Oncology.","from":"paper-sunrise-1-jco-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for pat...","note":"Burstein HJ, Curigliano G, Gnant M, et al. Annals of Oncology.","from":"paper-st-gallen-2025-consensus-ann-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlle...","note":"Agarwal N, Azad AA, Carles J, et al. The Lancet.","from":"paper-talapro-2-lancet-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","note":"Jain H, Karulkar A, Kalra D, et al. Lancet Haematology.","from":"paper-jain-talicabtagene-lancet-haem-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","note":"Mountzios G, Sun L, Cho BC, et al. New England Journal of Medicine.","from":"paper-tarlatamab-sclc-n-engl-j-med-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population","note":"Erices JI, Gonzalez E, Salgado M, et al. Frontiers in Oncology.","from":"paper-erices-chilean-gallbladder-landscape-front-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient","note":"Gilene S, Haacker L, Rutan H, Pressey JG. Pediatric Blood & Cancer.","from":"paper-gilene-ivermectin-toxicity-paediatric-oncology-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","note":"Modi S, Jacot W, Iwata H, et al. Nature Medicine.","from":"paper-destiny-breast04-nat-med-2025-update","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreati...","note":"Hammel P, Metges JP, Macarulla Mercade T, et al. Journal of Clinical Oncology.","from":"paper-hammel-j-clin-oncol","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Stu...","note":"Babiker HM, Picozzi V, Chandana SR, et al. Journal of Clinical Oncology.","from":"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report","note":"Riely GJ, Ahn MJ, Clarke JM, et al. Journal of Thoracic Oncology.","from":"paper-pharos-j-thorac-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline","note":"Trapani D, Martins-Branco D, Curigliano G, et al. Annals of Oncology.","from":"paper-esmo-mbc-living-guideline-update-ann-oncol-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","note":"Hecht JR, Park YS, Tabernero J, et al. The Lancet.","from":"paper-nct05425940-lancet-2025","refs":[]},{"group":"paper","date":"2025","precision":"year","title":"Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chem...","note":"Piotrowska Z, Passaro A, Nguyen D, et al. Journal of Clinical Oncology.","from":"paper-nct04036682-j-clin-oncol-2025","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"A Core Outcome Set for Adult General ICU Patients","note":"Crit Care Med","from":"tomas-jovaisa","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"A deliverable national cancer control plan for the UK: lessons from abroad and the need for discipline at home","note":"The Lancet Oncology","from":"cary-adams","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","note":"Cancers","from":"diane-simeone","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer","note":"npj Precision Oncology","from":"gary-middleton","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patient...","note":"Gynecologic Oncology","from":"thomas-herzog","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study","note":"Medical Sciences","from":"magdolna-dank","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological...","note":"J Clin Med","from":"refik-emre-cecen","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","note":"New England Journal of Medicine","from":"rachel-rau","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children (AALL1731)","note":"NEJM","from":"sumit-gupta","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Cancer du poumon non à petites cellules métastatique du sujet âgé et immunothérapie. Traiter ou s’abstenir?","note":"Revue Médicale Suisse","from":"alfredo-addeo","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Cancer incidence and diagnostic characteristics in people with intellectual disabilities in the Netherlands: a national registry-based cohort study","note":"BMJ Oncology","from":"geraline-leusink","refs":["haiko-bloemendal"]},{"group":"person-paper","date":"2025","precision":"year","title":"Cancer screening participation and outcomes among people with an intellectual disability in the Netherlands: a cross-sectional population-based study","note":"The Lancet Public Health","from":"geraline-leusink","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","note":"New England Journal of Medicine","from":"james-larkin","refs":["f-stephen-hodi","jedd-wolchok"]},{"group":"person-paper","date":"2025","precision":"year","title":"Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 final results","note":"JCO","from":"jesus-berdeja","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Clinical Evidence 2030","note":"Clin Pharmacol Ther","from":"emer-cooke","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Clinical presentation of bone tumours in children and young people: a systematic review and meta-analysis","note":"Archives of Disease in Childhood","from":"ashley-ball-gamble","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Comparing strategies for lung cancer screening eligibility: results from the Yorkshire Lung Screening Trial","note":"Journal of Thoracic Oncology","from":"matthew-callister","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Comparing the Costs of Surveillance of Early-Stage Breast Cancer by Digital or Traditional Follow-Up Methods: Randomized Crossover Study","note":"JMIR Cancer","from":"johanna-mattson","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer (TROPION-Breast01)","note":"Journal of Clinical Oncology","from":"sara-tolaney","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer (TROPION-Lung01)","note":"JCO","from":"benjamin-besse","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Do national cancer control plans address care and research for children, adolescents, and young adults? A review of status, priorities, and recommendations acro...","note":"The Lancet Regional Health - Europe","from":"gilles-vassal","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind...","note":"The Lancet","from":"bruno-sangro","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma","note":"International Journal of Gynecological Cancer","from":"ane-gerda-eriksson","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Encorafenib, cetuximab, and chemotherapy in BRAF-mutated colorectal cancer (BREAKWATER)","note":"NEJM","from":"scott-kopetz","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer (BREAKWATER)","note":"NEJM","from":"josep-tabernero","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","note":"Lancet Oncology","from":"nicole-concin","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"European Registry of Hereditary Pancreatic Diseases (EUROPAC): protocol for primary and secondary screening in individuals at high risk of pancreatic cancer","note":"BMJ Open","from":"chris-halloran","refs":["bill-greenhalf"]},{"group":"person-paper","date":"2025","precision":"year","title":"Expedited pathway insights: Unveiling oncology and non-oncology drug approvals and withdrawals of USFDA and EMA","note":"Critical Reviews in Oncology/Hematology","from":"rajeev-singh-raghuvanshi","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Exploring the clinical trials, regulatory insights, and challenges of PROTACs in oncology","note":"Seminars in Oncology","from":"rajeev-singh-raghuvanshi","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non–Small Cell Lung Cancer","note":"Clinical Cancer Research","from":"martin-schuler","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma","note":"Nature Communications","from":"marco-herold","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"High rate of cytokine release syndrome-related coagulopathy with low incidence of bleeding and thrombosis in patients treated with BCMA-targeted CAR-T","note":"Cancers","from":"polina-stepensky","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer","note":"Future Oncology","from":"taofeek-owonikoko","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Imlunestrant with or without abemaciclib in advanced breast cancer (EMBER-3)","note":"NEJM","from":"komal-jhaveri","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Intraoperative radiation therapy for glioblastoma and brain metastases: Program development and initial experience from the Philippines","note":"Journal of Clinical Neuroscience","from":"gerardo-legaspi","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2)","note":"Lancet","from":"zhou-caicun","refs":["qing-zhou"]},{"group":"person-paper","date":"2025","precision":"year","title":"Long-term survival with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma (CheckMate 067)","note":"New England Journal of Medicine","from":"f-stephen-hodi","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors","note":"Journal of the National Comprehensive Cancer Network","from":"emily-bergsland","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","note":"JCO","from":"ghayas-issa","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Neoadjuvant and adjuvant pembrolizumab in advanced head and neck squamous cell carcinoma (KEYNOTE-689)","note":"NEJM","from":"ravindra-uppaluri","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52...","note":"Nature Cancer","from":"christian-singer","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer","note":"Endocrine-Related Cancer","from":"ueno-takayuki","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"p53 regulates the expression of histone modifiers to restrict stemness and maintain differentiation","from":"moshe-oren","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome","note":"Blood Advances","from":"pavan-reddy","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"PEGylation technology: addressing concerns, moving forward","from":"yechezkel-barenholz","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer: overall survival and progression-free survival by mismatch repair status","note":"JCO","from":"ramez-eskander","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously...","note":"Cancer","from":"taofeek-owonikoko","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins","note":"Cell Death & Differentiation","from":"marco-herold","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Structured exercise after adjuvant chemotherapy for colon cancer (CHALLENGE)","note":"NEJM","from":"kerry-courneya","refs":["christopher-booth"]},{"group":"person-paper","date":"2025","precision":"year","title":"Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2","note":"BMC Cancer","from":"andrew-biankin","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study","note":"Lancet Haematology","from":"purwar-rahul","refs":["jain-hasmukh"]},{"group":"person-paper","date":"2025","precision":"year","title":"Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies","note":"Annual Review of Pharmacology and Toxicology","from":"john-stagg","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing","note":"Journal of Thoracic Oncology","from":"karen-kelly","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"The Global Platform for Access to Childhood Cancer Medicines: addressing inequities in childhood cancer care","note":"The Lancet Oncology","from":"tedros-adhanom-ghebreyesus","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","note":"Annals of Oncology","from":"sara-lopez-tarruella","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Trastuzumab deruxtecan in HER2-low or HER2-ultralow, hormone receptor-positive metastatic breast cancer (DESTINY-Breast06)","note":"NEJM","from":"giuseppe-curigliano","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive advanced breast cancer (DESTINY-Breast09)","note":"NEJM","from":"cristina-saura","refs":[]},{"group":"person-paper","date":"2025","precision":"year","title":"Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy","note":"Journal of Thoracic Oncology","from":"martin-schuler","refs":[]},{"group":"regulatory","date":"2025","precision":"year","title":"Eflornithine (DFMO): filing (EU)","note":"MAA submitted to EMA, UK, Australia, Switzerland","from":"eflornithine","refs":[]},{"group":"regulatory","date":"2025","precision":"year","title":"Nirogacestat: approval (EU)","note":"European Commission approval","from":"nirogacestat","refs":[]},{"group":"regulatory","date":"2025","precision":"year","title":"Rinatabart sesutecan: designation (US)","note":"Breakthrough Therapy designation, advanced endometrial cancer after PD-(L)1 and platinum","from":"rinatabart-sesutecan","refs":[]},{"group":"regulatory","date":"2025","precision":"year","title":"Serplulimab: approval (UK)","note":"MHRA approval","from":"serplulimab","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"Aidoc CARE (clinical radiology foundation model)","note":"First use in humans or first approval, as the technology record states it.","from":"aidoc-care","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"AlphaGenome","note":"First use in humans or first approval, as the technology record states it.","from":"alphagenome","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"Atlas (Aignostics, Mayo Clinic, Charité)","note":"First use in humans or first approval, as the technology record states it.","from":"atlas-aignostics","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"BioEmu (Microsoft)","note":"First use in humans or first approval, as the technology record states it.","from":"bioemu","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"Cell2Sentence / C2S-Scale (Yale, Google)","note":"First use in humans or first approval, as the technology record states it.","from":"c2s-scale","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"CT-FM (whole-body CT foundation model)","note":"First use in humans or first approval, as the technology record states it.","from":"ct-fm","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"Evo 2 (Arc Institute, NVIDIA)","note":"First use in humans or first approval, as the technology record states it.","from":"evo2","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"Midnight (kaiko.ai)","note":"First use in humans or first approval, as the technology record states it.","from":"kaiko-midnight","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"MUSK (Stanford, vision-language pathology)","note":"First use in humans or first approval, as the technology record states it.","from":"musk","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"State (Arc Institute perturbation model)","note":"First use in humans or first approval, as the technology record states it.","from":"state-arc","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"Structured exercise programmes after curative treatment","note":"First use in humans or first approval, as the technology record states it.","from":"structured-exercise-survivorship","refs":[]},{"group":"technology","date":"2025","precision":"year","title":"TranscriptFormer and rBio (CZI virtual cell models)","note":"First use in humans or first approval, as the technology record states it.","from":"transcriptformer","refs":[]},{"group":"trial","date":"2025","precision":"year","title":"[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma reported","from":"nct04252859","refs":["breast-cancer"]},{"group":"trial","date":"2025","precision":"year","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or I...","from":"nct03602859","refs":["ovarian","niraparib","dostarlimab"]},{"group":"trial","date":"2025","precision":"year","title":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa reported","from":"nct04680052","refs":["follicular-lymphoma","tafasitamab","rituximab","lenalidomide"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer reported","from":"nct03706365","refs":["prostate","prostate-mcrpc","abemaciclib","abiraterone"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growt...","from":"nct04988295","refs":["nsclc","egfr-mutant-nsclc","lazertinib","amivantamab"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutat...","from":"nct03182244","refs":["aml","aml-flt3","gilteritinib","cytarabine"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition reported","from":"nct05061134","refs":["melanoma","advanced-melanoma","ceralasertib","durvalumab"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) repo...","from":"nct05460273","refs":["nsclc","tnbc","tnbc-metastatic","datopotamab-deruxtecan"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients reported","from":"nct03706690","refs":["nsclc","stage-iii-unresectable-nsclc","durvalumab"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP reported","from":"nct04971226","refs":["cml","cml-chronic-phase","imatinib","nilotinib"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With reported","from":"nct06212752","refs":["nsclc","sclc","pemetrexed","cisplatin"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With reported","from":"nct05722015","refs":["nsclc","sclc","pemetrexed","cisplatin"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) reported","from":"nct05020015","refs":["non-hodgkin-lymphoma"]},{"group":"trial","date":"2025","precision":"year","title":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) reported","note":"Objective response 30 percent across 158 evaluable NRG1 fusion-positive cancers, 42 percent (15 of 36) in pancreatic cancer; median duration of response 11.1 months; median progres...","from":"nct02912949","refs":["nsclc","pancreatic","kras-wild-type-pdac","metastatic-pdac"]},{"group":"trial","date":"2025","precision":"year","title":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL reported","from":"nct04624633","refs":["cll","acalabrutinib","umbralisib"]},{"group":"trial","date":"2025","precision":"year","title":"Actuate 1801 Part 3B (elraglusib) reported","note":"Overall survival longer with elraglusib in a randomised phase 2; confirmation pending.","from":"actuate-1801","refs":["pancreatic","metastatic-pdac","elraglusib","gemcitabine-nab-paclitaxel"]},{"group":"trial","date":"2025","precision":"year","title":"ALASCCA reported","note":"3-year recurrence HR 0.49 (PIK3CA hotspot) and 0.42 (other PI3K alterations).","from":"alascca","refs":["colorectal","aspirin"]},{"group":"trial","date":"2025","precision":"year","title":"ALEXANDRA / IMpassion030 reported","note":"iDFS HR 1.11 (0.87 to 1.42), p 0.38; stopped for futility at 2,199 of 2,300 patients.","from":"impassion030","refs":["tnbc","tnbc-early","atezolizumab","paclitaxel"]},{"group":"trial","date":"2025","precision":"year","title":"ALKOVE-1 reported","note":"ORR 31% in heavily pretreated ALK+ NSCLC; NDA under priority review.","from":"alkove-1","refs":["nsclc","alk-positive-nsclc","neladalkib"]},{"group":"trial","date":"2025","precision":"year","title":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo reported","from":"nct06956170","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","pomalidomide"]},{"group":"trial","date":"2025","precision":"year","title":"ALPHAMEDIX-02 reported","note":"ORR 54.3% (PRRT-naive); all primary endpoints met.","from":"alphamedix-02","refs":["neuroendocrine","alphamedix"]},{"group":"trial","date":"2025","precision":"year","title":"ASCENT-03 reported","note":"PFS HR 0.62.","from":"ascent-03","refs":["tnbc","tnbc-metastatic","sacituzumab-govitecan"]},{"group":"trial","date":"2025","precision":"year","title":"ASCENT-04 / KEYNOTE-D19 reported","note":"PFS HR 0.65; PFS2 improved.","from":"ascent-04","refs":["tnbc","tnbc-metastatic","sacituzumab-govitecan","pembrolizumab"]},{"group":"trial","date":"2025","precision":"year","title":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients reported","from":"nct03829462","refs":["rectal-cancer","colon-cancer","regorafenib","folfiri"]},{"group":"trial","date":"2025","precision":"year","title":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) reported","from":"nct03974022","refs":["nsclc","sclc","egfr-mutant-nsclc","her2-mutant-nsclc"]},{"group":"trial","date":"2025","precision":"year","title":"ATOMIC (Alliance A021502) reported","note":"3-year DFS 86.4% vs 76.6%, HR 0.50.","from":"atomic","refs":["colorectal","msi-high-colorectal","atezolizumab","folfox"]},{"group":"trial","date":"2025","precision":"year","title":"Beamion LUNG-1 reported","note":"Confirmed response rate 71% in 75 previously treated patients naive to HER2-directed therapy; 48% after a HER2 antibody-drug conjugate; FDA accelerated approval August 2025.","from":"beamion-lung-1","refs":["nsclc","her2-mutant-nsclc","zongertinib","trastuzumab-deruxtecan"]},{"group":"trial","date":"2025","precision":"year","title":"BREAKWATER reported","note":"OS 30.3 vs 15.1 months (HR 0.49); PFS 12.8 vs 7.1 months.","from":"breakwater","refs":["colorectal","braf-v600e-colorectal","encorafenib","cetuximab"]},{"group":"trial","date":"2025","precision":"year","title":"BWEL (Breast Cancer Weight Loss, Alliance A011401) reported","note":"Weight loss achieved; primary iDFS endpoint not met at first analysis (presented 2025; publication pending, verify).","from":"bwel","refs":["breast-hr-positive","breast-her2-positive"]},{"group":"trial","date":"2025","precision":"year","title":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma) reported","note":"Disease-free survival at 24 months 87.1 per cent with adjuvant cemiplimab against 64.1 per cent with placebo (hazard ratio 0.32, 95 per cent confidence interval 0.20 to 0.51, p<0.0...","from":"c-post","refs":["cutaneous-scc","advanced-cutaneous-scc","skin-cancer","cemiplimab"]},{"group":"trial","date":"2025","precision":"year","title":"CAPItello-281 reported","note":"Median rPFS 33.2 against 25.7 months, HR 0.81 (95% CI 0.66 to 0.98, p=0.034); OS HR 0.90 at 26.4% maturity; approved 2026.","from":"capitello-281","refs":["prostate","prostate-mhspc","capivasertib","abiraterone"]},{"group":"trial","date":"2025","precision":"year","title":"CHALLENGE (CCTG CO.21) reported","note":"DFS HR 0.72; OS HR 0.63; 8-year OS 90.3% vs 83.2%.","from":"challenge","refs":["colorectal","folfox"]},{"group":"trial","date":"2025","precision":"year","title":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame reported","from":"nct06868654","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","daratumumab"]},{"group":"trial","date":"2025","precision":"year","title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer reported","from":"nct04082364","refs":["gastric-her2-positive","margetuximab","retifanlimab","trastuzumab"]},{"group":"trial","date":"2025","precision":"year","title":"COMPETE reported","note":"PFS 23.9 vs 14.1 months, HR 0.67.","from":"compete","refs":["neuroendocrine","pancreatic-net","small-intestinal-net","itm-11"]},{"group":"trial","date":"2025","precision":"year","title":"CONKO-007 reported","note":"Overall R0 resection rate 25 percent with chemoradiotherapy against 18 percent with chemotherapy (p 0.113); R0 among operated patients 69.4 against 50.0 percent (p 0.04); overall s...","from":"conko-007","refs":["pancreatic","locally-advanced-pdac","folfirinox","gemcitabine"]},{"group":"trial","date":"2025","precision":"year","title":"CT041-ST-01 reported","note":"Median progression-free survival 3.25 vs 1.77 months (hazard ratio 0.37) in 156 randomised patients.","from":"nct04581473","refs":["gastric","gastric-cldn18-2-positive","satricabtagene-autoleucel"]},{"group":"trial","date":"2025","precision":"year","title":"DeLLphi-304 reported","note":"OS HR 0.60.","from":"dellphi-304","refs":["sclc","extensive-stage-sclc","tarlatamab","amrubicin"]},{"group":"trial","date":"2025","precision":"year","title":"DESTINY-Breast05 reported","note":"3-year iDFS 92.4% vs 83.7%, HR 0.47.","from":"destiny-breast05","refs":["breast-her2-positive","her2-positive-early-breast-cancer","trastuzumab-deruxtecan","trastuzumab-emtansine"]},{"group":"trial","date":"2025","precision":"year","title":"DESTINY-Breast09 reported","note":"PFS HR 0.56.","from":"destiny-breast09","refs":["breast-her2-positive","trastuzumab-deruxtecan"]},{"group":"trial","date":"2025","precision":"year","title":"DESTINY-Breast11 reported","note":"pCR 67.3% vs 56.3%.","from":"destiny-breast11","refs":["breast-her2-positive","her2-positive-early-breast-cancer","trastuzumab-deruxtecan"]},{"group":"trial","date":"2025","precision":"year","title":"DESTINY-Gastric04 reported","note":"OS 14.7 vs 11.4 months, HR 0.70.","from":"destiny-gastric04","refs":["gastric","gastric-her2-positive","trastuzumab-deruxtecan","ramucirumab"]},{"group":"trial","date":"2025","precision":"year","title":"DYNAMIC-III reported","note":"ctDNA is strongly prognostic (three-year recurrence-free survival 87 against 49 percent) but de-escalation was not non-inferior and escalation did not help.","from":"dynamic-iii","refs":["colorectal","colon-cancer","signatera","folfox"]},{"group":"trial","date":"2025","precision":"year","title":"ECLIPSE reported","note":"rPFS significantly improved.","from":"eclipse-psma","refs":["prostate","prostate-mcrpc","lu177-psma-it"]},{"group":"trial","date":"2025","precision":"year","title":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene M...","from":"nct04915755","refs":["tnbc","tnbc-early","niraparib"]},{"group":"trial","date":"2025","precision":"year","title":"EV-303 / KEYNOTE-905 reported","note":"EFS HR 0.40; OS HR 0.50; pCR 57.1% vs 8.6%.","from":"ev-303","refs":["urothelial","enfortumab-vedotin","pembrolizumab"]},{"group":"trial","date":"2025","precision":"year","title":"EV-304 / KEYNOTE-B15 reported","note":"EFS, OS, and pCR significantly improved (topline; details pending).","from":"ev-304","refs":["urothelial","enfortumab-vedotin","pembrolizumab"]},{"group":"trial","date":"2025","precision":"year","title":"evERA reported","note":"PFS HR 0.56 (ITT); HR 0.38 (ESR1-mutant).","from":"evera","refs":["breast-hr-positive","hr-positive-metastatic-post-cdk46","giredestrant","everolimus"]},{"group":"trial","date":"2025","precision":"year","title":"FORTITUDE-101 reported","note":"Interim OS 17.9 vs 12.5 months (HR 0.61); benefit attenuated on follow-up.","from":"fortitude-101","refs":["gastric","bemarituzumab","folfox"]},{"group":"trial","date":"2025","precision":"year","title":"frontMIND reported","note":"PFS HR 0.75; 2-year PFS 71.1% vs 62.9%.","from":"frontmind","refs":["dlbcl","tafasitamab","lenalidomide"]},{"group":"trial","date":"2025","precision":"year","title":"HER2CLIMB-05 reported","note":"PFS 24.9 vs 16.3 months, HR 0.64.","from":"her2climb-05","refs":["breast-her2-positive","her2-positive-breast-brain-metastases","tucatinib","trastuzumab"]},{"group":"trial","date":"2025","precision":"year","title":"HERTHENA-Lung02 reported","note":"PFS HR 0.77 (5.8 vs 5.4 months); OS not significant; BLA withdrawn.","from":"herthena-lung02","refs":["nsclc","egfr-mutant-nsclc","patritumab-deruxtecan"]},{"group":"trial","date":"2025","precision":"year","title":"HORIZON-Breast01 reported","note":"PFS 30.6 vs 8.3 months, HR 0.22.","from":"horizon-breast01","refs":["breast-her2-positive","trastuzumab-rezetecan","pyrotinib"]},{"group":"trial","date":"2025","precision":"year","title":"HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL reported","from":"nct06149247","refs":["cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma","hypericin-sgx301"]},{"group":"trial","date":"2025","precision":"year","title":"IMforte reported","note":"OS 13.2 vs 10.6 months (HR 0.73); PFS HR 0.54.","from":"imforte","refs":["sclc","extensive-stage-sclc","lurbinectedin","atezolizumab"]},{"group":"trial","date":"2025","precision":"year","title":"iMMagine-1 reported","note":"ORR 97%.","from":"immagine-1","refs":["multiple-myeloma","anitocabtagene-autoleucel"]},{"group":"trial","date":"2025","precision":"year","title":"IMvigor011 reported","note":"DFS HR 0.64; OS HR 0.59 in ctDNA+.","from":"imvigor011","refs":["urothelial","atezolizumab","signatera"]},{"group":"trial","date":"2025","precision":"year","title":"INSEMA (Intergroup Sentinel Mamma) reported","note":"Five-year invasive disease-free survival 91.9 percent without axillary surgery against 91.7 percent with sentinel node biopsy (hazard ratio 0.91, 0.73 to 1.14, non-inferior); axill...","from":"insema","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2025","precision":"year","title":"IoN reported","note":"5-year recurrence-free ~98% (no RAI) vs ~96% (RAI).","from":"ion-trial","refs":["thyroid"]},{"group":"trial","date":"2025","precision":"year","title":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex reported","from":"nct06868667","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin","daratumumab"]},{"group":"trial","date":"2025","precision":"year","title":"KEYNOTE-641 reported","note":"Median overall survival 24.7 against 27.3 months (hazard ratio 1.04, 95 percent confidence interval 0.88 to 1.22) and radiographic progression-free survival 10.4 against 9.0 months...","from":"keynote-641","refs":["prostate","prostate-mcrpc","pembrolizumab","enzalutamide"]},{"group":"trial","date":"2025","precision":"year","title":"KEYNOTE-689 reported","note":"Median EFS 59.7 vs 29.6 months (CPS ≥1).","from":"keynote-689","refs":["head-and-neck","hpv-negative-head-and-neck-cancer","pembrolizumab"]},{"group":"trial","date":"2025","precision":"year","title":"KEYNOTE-921 reported","note":"Median radiographic progression-free survival 8.6 against 8.3 months (hazard ratio 0.85, 95 percent confidence interval 0.71 to 1.01) and overall survival 19.6 against 19.0 months...","from":"keynote-921","refs":["prostate","prostate-mcrpc","pembrolizumab","docetaxel"]},{"group":"trial","date":"2025","precision":"year","title":"KEYNOTE-991 reported","note":"Radiographic progression-free survival hazard ratio 1.20 (95 percent confidence interval 0.96 to 1.49, p=0.9467), medians not reached; stopped for futility.","from":"keynote-991","refs":["prostate","prostate-mhspc","pembrolizumab","enzalutamide"]},{"group":"trial","date":"2025","precision":"year","title":"KEYNOTE-B96 / ENGOT-ov65 reported","note":"OS 18.2 vs 14.0 months in CPS ≥1 (HR 0.76); ITT OS HR 0.82.","from":"keynote-b96","refs":["ovarian","platinum-resistant-ovarian-cancer","pembrolizumab","paclitaxel"]},{"group":"trial","date":"2025","precision":"year","title":"KOMET-001 reported","note":"CR 23%, ORR 33%, median OS 6.6 months.","from":"komet-001","refs":["aml","aml-npm1-kmt2a","ziftomenib"]},{"group":"trial","date":"2025","precision":"year","title":"lidERA reported","note":"iDFS ~30% relative reduction (HR ~0.70).","from":"lidera","refs":["breast-hr-positive","hr-positive-early-high-risk","giredestrant"]},{"group":"trial","date":"2025","precision":"year","title":"MajesTEC-3 reported","note":"36-month PFS 83.4% vs 29.7%; HR ~0.17.","from":"majestec-3","refs":["multiple-myeloma","myeloma-relapsed-refractory","teclistamab","daratumumab"]},{"group":"trial","date":"2025","precision":"year","title":"MATTERHORN reported","note":"EFS HR 0.71; OS HR 0.78; 3-year OS 68.6%.","from":"matterhorn","refs":["gastric","durvalumab","flot"]},{"group":"trial","date":"2025","precision":"year","title":"NIVOPOSTOP (GORTEC 2018-01) reported","note":"Three-year disease-free survival 63.1% vs 52.5% (hazard ratio 0.76).","from":"nivopostop","refs":["head-and-neck","hpv-negative-head-and-neck-cancer","nivolumab","cisplatin"]},{"group":"trial","date":"2025","precision":"year","title":"NRG-HN002 & NRG-HN005 (HPV+ de-escalation) reported","note":"HN005: de-escalated arms had worse PFS; control 2-year PFS 98%.","from":"nrg-hn002-hn005","refs":["head-and-neck","oropharyngeal-cancer","hpv-positive-oropharyngeal-cancer"]},{"group":"trial","date":"2025","precision":"year","title":"NSABP B-51 / RTOG 1304 reported","note":"Regional nodal irradiation after a complete nodal response to chemotherapy did not lengthen the invasive breast cancer recurrence-free interval (hazard ratio 0.88, 0.60 to 1.28, p=...","from":"nsabp-b51","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2025","precision":"year","title":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma r...","from":"nct02506959","refs":["plasma-cell-leukaemia","busulfan","gemcitabine","melphalan"]},{"group":"trial","date":"2025","precision":"year","title":"PANOVA-3 reported","note":"OS 16.2 vs 14.2 months, HR 0.82.","from":"panova-3","refs":["pancreatic","locally-advanced-pdac","optune","gemcitabine-nab-paclitaxel"]},{"group":"trial","date":"2025","precision":"year","title":"PATHFINDER 2 reported","from":"pathfinder-2","refs":["galleri"]},{"group":"trial","date":"2025","precision":"year","title":"Patidegib gel in Gorlin syndrome (phase 2A) reported","note":"Post hoc analyses in 17 participants suggested that patidegib topical gel reduced the number of new surgically eligible basal cell carcinomas and the level of hedgehog signalling...","from":"patidegib-gel-gorlin-phase-2","refs":["basal-cell-carcinoma","skin-cancer","patidegib"]},{"group":"trial","date":"2025","precision":"year","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-768...","from":"nct05224141","refs":["sclc","extensive-stage-sclc","pembrolizumab","etoposide"]},{"group":"trial","date":"2025","precision":"year","title":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers reported","from":"nct03260023","refs":["penile","node-positive-penile-cancer","avelumab"]},{"group":"trial","date":"2025","precision":"year","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy reported","from":"nct03334617","refs":["nsclc","sclc","durvalumab","ceralasertib"]},{"group":"trial","date":"2025","precision":"year","title":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma) reported","note":"Objective response in 54.5 per cent (95 per cent confidence interval 44.2 to 64.4) with complete responses in 17.8 per cent, median progression-free survival 16.0 months, and 63 pe...","from":"pod1um-201","refs":["merkel-cell-carcinoma","skin-cancer","retifanlimab"]},{"group":"trial","date":"2025","precision":"year","title":"POD1UM-303/InterAACT-2 reported","note":"Median progression-free survival 9.3 months with retifanlimab plus carboplatin-paclitaxel against 7.4 months with placebo (hazard ratio 0.63, one-sided p 0.0006); approved in the U...","from":"pod1um-303","refs":["metastatic-anal-cancer","anal","retifanlimab","carboplatin"]},{"group":"trial","date":"2025","precision":"year","title":"POTOMAC reported","note":"DFS HR 0.68.","from":"potomac","refs":["urothelial","durvalumab","bcg-intravesical"]},{"group":"trial","date":"2025","precision":"year","title":"Pre-BRA (pre-pectoral breast reconstruction evaluation) reported","note":"Implant loss 8.2 percent at three months and a complication in 42.0 percent; physical and sexual wellbeing fell significantly against baseline at three and eighteen months, and two...","from":"pre-bra","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2025","precision":"year","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies reported","from":"nct05316701","refs":["aml","mds","tregzi"]},{"group":"trial","date":"2025","precision":"year","title":"PREEMPT CRC reported","note":"Sensitivity 79.2% for colorectal cancer and specificity 91.5% for advanced colorectal neoplasia (n = 27,010 evaluable); all primary endpoints met; advanced precancerous lesion sens...","from":"preempt-crc","refs":["colorectal","simplescreen-crc"]},{"group":"trial","date":"2025","precision":"year","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions reported","from":"nct05663866","refs":["nsclc","egfr-mutant-nsclc","dexamethasone","methotrexate"]},{"group":"trial","date":"2025","precision":"year","title":"PREOPANC-2 reported","note":"Median overall survival 21.9 months with neoadjuvant FOLFIRINOX against 21.3 months with neoadjuvant gemcitabine chemoradiotherapy and adjuvant gemcitabine (hazard ratio 0.88, 95 p...","from":"preopanc-2","refs":["pancreatic","resectable-pdac","borderline-resectable-pdac","folfirinox"]},{"group":"trial","date":"2025","precision":"year","title":"PSMAddition reported","note":"rPFS HR 0.72 (95% CI 0.58 to 0.90, p=0.0021), medians not reached in either arm at the second interim analysis; overall survival not yet reported.","from":"psmaddition","refs":["prostate","prostate-mhspc","pluvicto"]},{"group":"trial","date":"2025","precision":"year","title":"RAINFOL-01 (Rina-S) reported","note":"ORR 55.6% (ovarian, 120 mg/m²); 50% (endometrial, 100 mg/m²).","from":"rainfol-01","refs":["ovarian","endometrial","rinatabart-sesutecan"]},{"group":"trial","date":"2025","precision":"year","title":"RELATIVITY-098 reported","note":"RFS not improved.","from":"relativity-098","refs":["melanoma","relatlimab-nivolumab","nivolumab"]},{"group":"trial","date":"2025","precision":"year","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome reported","from":"nct02521493","refs":["aml","leukaemia","asparaginase","crisantaspase"]},{"group":"trial","date":"2025","precision":"year","title":"ROMAN reported","note":"Severe oral mucositis incidence 54% vs 64% (relative risk 0.84, 95% CI 0.71 to 1.00; p = 0.045); median duration 8 vs 18 days (p = 0.002).","from":"roman","refs":["head-and-neck","avasopasem-manganese","cisplatin"]},{"group":"trial","date":"2025","precision":"year","title":"ROSELLA / GOG-3073 reported","note":"OS 16.0 vs 11.9 months (HR 0.69).","from":"rosella","refs":["ovarian","platinum-resistant-ovarian-cancer","relacorilant","paclitaxel"]},{"group":"trial","date":"2025","precision":"year","title":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients reported","from":"nct05222555","refs":["dlbcl","tafasitamab","lenalidomide"]},{"group":"trial","date":"2025","precision":"year","title":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours report...","from":"nct04999969","refs":["metastatic-cancer","durvalumab","gemcitabine"]},{"group":"trial","date":"2025","precision":"year","title":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma) reported","note":"Freedom from treatment failure at five years 77.8 per cent after curettage with imiquimod against 98.2 per cent after surgical excision; relative risk of failure 15.93 (95 per cent...","from":"scin-trial","refs":["basal-cell-carcinoma","skin-cancer","imiquimod"]},{"group":"trial","date":"2025","precision":"year","title":"SERENA-6 reported","note":"PFS 16.0 vs 9.2 months, HR 0.44.","from":"serena-6","refs":["breast-hr-positive","hr-positive-metastatic-post-cdk46","camizestrant"]},{"group":"trial","date":"2025","precision":"year","title":"SOHO-01 reported","note":"ORR ~64%; accelerated approval Nov 2025.","from":"soho-01","refs":["nsclc","her2-mutant-nsclc","sevabertinib"]},{"group":"trial","date":"2025","precision":"year","title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma reported","from":"nct04044768","refs":["sarcoma","liposarcoma","synovial-sarcoma","afamitresgene-autoleucel"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma reported","from":"nct02180711","refs":["hodgkin-lymphoma","non-hodgkin-lymphoma","acalabrutinib","rituximab"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign reported","from":"nct03932331","refs":["mantle-cell-lymphoma","acalabrutinib"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia reported","from":"nct04075292","refs":["cll","cll-treatment-naive","acalabrutinib","rituximab"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer reported","from":"nct04665856","refs":["sclc","extensive-stage-sclc","tiragolumab","atezolizumab"]},{"group":"trial","date":"2025","precision":"year","title":"Study of AZD2811 + Durvalumab in ES-SCLC reported","from":"nct04745689","refs":["sclc","extensive-stage-sclc","durvalumab","carboplatin"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC reported","from":"nct04446117","refs":["prostate","prostate-mcrpc","cabozantinib","atezolizumab"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece reported","from":"nct03755791","refs":["hcc","hcc-advanced","cabozantinib","sorafenib"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell L...","from":"nct05445843","refs":["nsclc","kras-g12c-nsclc","jdq443"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patient...","from":"nct04778397","refs":["aml","magrolimab","venetoclax","azacitidine"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia reported","from":"nct05079230","refs":["aml","magrolimab","venetoclax","azacitidine"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participa...","from":"nct03036098","refs":["urothelial","muscle-invasive-bladder-cancer","nivolumab","ipilimumab"]},{"group":"trial","date":"2025","precision":"year","title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) reported","from":"nct05089734","refs":["nsclc","sclc","sacituzumab-govitecan","docetaxel"]},{"group":"trial","date":"2025","precision":"year","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) reported","from":"nct05171816","refs":["prostate","prostate-mcrpc","olaparib","abiraterone"]},{"group":"trial","date":"2025","precision":"year","title":"Study to Compare the Efficacy and Safety of F-627 and GRAN® reported","from":"nct04174599","refs":["breast-cancer","efbemalenograstim-alfa","filgrastim"]},{"group":"trial","date":"2025","precision":"year","title":"Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases reported","from":"nct04410133","refs":["secondary-brain-tumours","fluciclovine-f18"]},{"group":"trial","date":"2025","precision":"year","title":"SUMMIT (lung health check study) reported","note":"261 lung cancers in 12,773 participants, 79.3 percent at stage 1 or 2; episode sensitivity 97.0 percent and false-positive rate 4.8 percent; uptake 1.89 times higher in the least d...","from":"summit-lung","refs":["nsclc","lung-cancer"]},{"group":"trial","date":"2025","precision":"year","title":"SUNMO reported","note":"PFS improved (HR reported 2025).","from":"sunmo","refs":["dlbcl","mosunetuzumab","polatuzumab-vedotin"]},{"group":"trial","date":"2025","precision":"year","title":"SUPREMO (BIG 2-04) reported","note":"Ten-year overall survival 81.4 percent with chest-wall irradiation against 81.9 percent without (hazard ratio 1.04, p=0.80); chest-wall recurrence 1.1 against 2.5 percent (hazard r...","from":"supremo","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2025","precision":"year","title":"SWOG S1815 reported","note":"OS 14.0 vs 13.6 months, HR 0.91 (0.72 to 1.14), p=0.41; PFS 7.5 vs 6.3 months, HR 0.89; gallbladder PFS interaction p=0.01, OS interaction p=0.28.","from":"swog-s1815","refs":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma"]},{"group":"trial","date":"2025","precision":"year","title":"SYMPATICO reported","note":"Median progression-free survival 31.9 months with ibrutinib plus venetoclax against 22.1 months with ibrutinib plus placebo (hazard ratio 0.629, p 0.0024); complete response 69.2 p...","from":"sympatico","refs":["mantle-cell-lymphoma","non-hodgkin-lymphoma","ibrutinib","venetoclax"]},{"group":"trial","date":"2025","precision":"year","title":"Talicabtagene autoleucel (NexCAR19) phase 1/2 reported","note":"ORR 73% (37 of 51) in relapsed or refractory B-cell malignancies; two treatment-related deaths.","from":"talicel-phase-1-2","refs":["dlbcl","all-leukemia","talicabtagene-autoleucel"]},{"group":"trial","date":"2025","precision":"year","title":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobi...","from":"nct04941287","refs":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma"]},{"group":"trial","date":"2025","precision":"year","title":"TROPION-Breast02 reported","note":"OS 23.7 vs 18.7 months; PFS also improved.","from":"tropion-breast02","refs":["tnbc","tnbc-metastatic","datopotamab-deruxtecan"]},{"group":"trial","date":"2025","precision":"year","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers reported","from":"nct04430738","refs":["gallbladder","tucatinib","trastuzumab","capox"]},{"group":"trial","date":"2025","precision":"year","title":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based...","from":"nct04524689","refs":["nsclc","tusamitamab-ravtansine","pembrolizumab","cisplatin"]},{"group":"trial","date":"2025","precision":"year","title":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors reported","from":"nct04659603","refs":["breast-cancer","tusamitamab-ravtansine","gemcitabine"]},{"group":"trial","date":"2025","precision":"year","title":"VERIFY reported","note":"Response (no phlebotomy eligibility) weeks 20 to 32: 77% vs 33%.","from":"verify","refs":["polycythaemia-vera","myeloproliferative-neoplasms","rusfertide"]},{"group":"trial","date":"2025","precision":"year","title":"VERITAC-2 reported","note":"PFS HR 0.57 in ESR1-mutant; ITT not significant.","from":"veritac-2","refs":["breast-hr-positive","vepdegestrant"]},{"group":"trial","date":"2025","precision":"year","title":"VERONA reported","note":"Venetoclax added to azacitidine did not significantly improve overall survival in untreated higher-risk myelodysplastic syndromes.","from":"verona","refs":["mds-higher-risk","mds","venetoclax","azacitidine"]},{"group":"trial","date":"2025","precision":"year","title":"YLST reported","note":"PLCOm2012 at 1.51 percent detected 91.1 percent of cancers against 62.8 percent for the 2013 USPSTF rule; incremental cost-effectiveness 3,797 to 4,013 pounds per quality-adjusted...","from":"ylst","refs":["nsclc","lung-cancer"]},{"group":"regulatory","date":"2025-01","precision":"month","title":"Panitumumab: approval (US)","note":"With sotorasib for KRAS G12C mCRC (CodeBreaK 300)","from":"panitumumab","refs":[]},{"group":"regulatory","date":"2025-01-16","precision":"day","title":"Sotorasib: approval (US)","note":"KRAS G12C colorectal cancer with panitumumab (CodeBreaK 300)","from":"sotorasib","refs":[]},{"group":"regulatory","date":"2025-01-17","precision":"day","title":"Datopotamab deruxtecan: approval (US)","note":"HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy (TROPION-Breast01)","from":"datopotamab-deruxtecan","refs":[]},{"group":"regulatory","date":"2025-01-27","precision":"day","title":"Trastuzumab deruxtecan: approval (US)","note":"HER2-low and HER2-ultralow HR+ breast cancer after endocrine therapy (DESTINY-Breast06)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2025-02","precision":"month","title":"Serplulimab: approval (EU)","note":"European Commission approval for ES-SCLC","from":"serplulimab","refs":[]},{"group":"regulatory","date":"2025-02","precision":"month","title":"Trastuzumab brengitecan: filing (China)","note":"Phase 3 vs T-DM1 in residual disease registered (NCT06830889)","from":"trastuzumab-brengitecan","refs":[]},{"group":"regulatory","date":"2025-02-14","precision":"day","title":"Vimseltinib: approval (US)","note":"MOTION","from":"vimseltinib","refs":[]},{"group":"guideline","date":"2025-03","precision":"month","title":"NCCN 2025 update for Prostate cancer","note":"1 row recategorised. Anchored to FDA approval of 177Lu-PSMA-617 before taxane chemotherapy, March 2025 (PSMAfore).","from":"prostate","refs":["pluvicto","psmafore","vision"]},{"group":"regulatory","date":"2025-03","precision":"month","title":"177Lu-edotreotide: designation (US)","note":"COMPETE topline at ENETS 2025","from":"itm-11","refs":[]},{"group":"regulatory","date":"2025-03","precision":"month","title":"AK146D1: filing (China)","note":"IND cleared; first-in-human phase 1 started","from":"ak146d1","refs":[]},{"group":"regulatory","date":"2025-03","precision":"month","title":"Camrelizumab + rivoceranib: complete response letter (US)","note":"Second CRL","from":"camrelizumab-rivoceranib","refs":[]},{"group":"regulatory","date":"2025-03","precision":"month","title":"Camrelizumab: complete response letter (US)","note":"Second complete response letter","from":"camrelizumab","refs":[]},{"group":"regulatory","date":"2025-03","precision":"month","title":"Datopotamab deruxtecan: approval (JP)","note":"First approval worldwide for HR+/HER2- breast cancer (December 2024, Japan MHLW)","from":"datopotamab-deruxtecan","refs":[]},{"group":"regulatory","date":"2025-03","precision":"month","title":"Sacituzumab tirumotecan: approval (China)","note":"EGFR-mutant NSCLC after TKI failure","from":"sacituzumab-tirumotecan","refs":[]},{"group":"regulatory","date":"2025-03-04","precision":"day","title":"Tislelizumab: approval (US)","note":"First-line ESCC PD-L1 ≥1% (RATIONALE-306)","from":"tislelizumab","refs":[]},{"group":"regulatory","date":"2025-03-26","precision":"day","title":"Cabozantinib: approval (US)","note":"NET indication on CABINET","from":"cabozantinib","refs":[]},{"group":"regulatory","date":"2025-03-28","precision":"day","title":"Durvalumab: approval (US)","note":"Perioperative muscle-invasive bladder cancer (NIAGARA)","from":"durvalumab","refs":[]},{"group":"regulatory","date":"2025-03-28","precision":"day","title":"Lutetium-177 vipivotide tetraxetan: approval (US)","note":"PSMA+ mCRPC after ARPI, before chemotherapy (PSMAfore)","from":"pluvicto","refs":[]},{"group":"guideline","date":"2025-04","precision":"month","title":"NCCN 2024-2025 updates for Colorectal cancer","note":"2 rows added, 1 row recategorised. Anchored to FDA approvals of adagrasib with cetuximab (June 2024), encorafenib with cetuximab and mFOLFOX6 in the first line (December 2024, BREA...","from":"colorectal","refs":["sotorasib","adagrasib","panitumumab","cetuximab"]},{"group":"regulatory","date":"2025-04","precision":"month","title":"Ipilimumab: approval (US)","note":"With nivolumab first-line MSI-H/dMMR colorectal cancer (CheckMate 8HW)","from":"ipilimumab","refs":[]},{"group":"regulatory","date":"2025-04","precision":"month","title":"Ivonescimab: approval (China)","note":"First-line PD-L1+ NSCLC (HARMONi-2)","from":"ivonescimab","refs":[]},{"group":"regulatory","date":"2025-05","precision":"month","title":"Belzutifan: approval (US)","note":"Pheochromocytoma/paraganglioma","from":"belzutifan","refs":[]},{"group":"regulatory","date":"2025-05","precision":"month","title":"Gedatolisib: designation (US)","note":"Breakthrough Therapy designation, PIK3CA-wild-type HR+/HER2- breast cancer after CDK4/6","from":"gedatolisib","refs":[]},{"group":"regulatory","date":"2025-05","precision":"month","title":"Patritumab deruxtecan: withdrawal (US)","note":"BLA withdrawn after HERTHENA-Lung02 met PFS but not OS","from":"patritumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2025-05","precision":"month","title":"Trastuzumab rezetecan: approval (China)","note":"HER2-mutant NSCLC","from":"trastuzumab-rezetecan","refs":[]},{"group":"regulatory","date":"2025-05-08","precision":"day","title":"Avutometinib + defactinib: approval (US)","note":"Accelerated approval on RAMP 201; RAMP 301 confirmatory","from":"avutometinib-defactinib","refs":[]},{"group":"regulatory","date":"2025-05-14","precision":"day","title":"Telisotuzumab vedotin: approval (US)","note":"Accelerated approval, previously treated c-MET-high non-squamous NSCLC (LUMINOSITY)","from":"telisotuzumab-vedotin","refs":[]},{"group":"regulatory","date":"2025-05-22","precision":"day","title":"Resminostat: complete response letter (EU)","note":"CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome","from":"resminostat","refs":[]},{"group":"guideline","date":"2025-06","precision":"month","title":"NCCN 2025 updates for Non-small-cell lung cancer","note":"1 row added, 1 row removed. Anchored to FDA approval of datopotamab deruxtecan for EGFR-mutant NSCLC after TKI and chemotherapy (June 2025, TROPION-Lung05); withdrawal of the patri...","from":"nsclc","refs":["datopotamab-deruxtecan","tropion-lung05","patritumab-deruxtecan","herthena-lung02"]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Adagrasib: approval (US)","note":"Full approval in NSCLC (KRYSTAL-12)","from":"adagrasib","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Ciltacabtagene autoleucel: label change (US)","note":"REMS requirements removed for CAR-T class","from":"ciltacabtagene-autoleucel","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Dostarlimab: designation (US)","note":"Breakthrough Therapy designation, dMMR locally advanced rectal cancer (organ preservation)","from":"dostarlimab","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Inavolisib: label change (US)","note":"OS benefit added to label","from":"inavolisib","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Lifileucel: approval (EU)","note":"Conditional marketing authorisation","from":"lifileucel","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Relacorilant: filing (US)","note":"NDA submitted (ROSELLA)","from":"relacorilant","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Shield: designation (US)","note":"Breakthrough Device designation for Shield multi-cancer (MCD)","from":"shield","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Tarlatamab: filing (US)","note":"Phase 3 DeLLphi-304 OS benefit presented; conversion to full approval pursued","from":"tarlatamab","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Vepdegestrant: filing (US)","note":"NDA submitted (VERITAC-2)","from":"vepdegestrant","refs":[]},{"group":"regulatory","date":"2025-06","precision":"month","title":"Vorasidenib: approval (EU)","note":"EMA approval","from":"vorasidenib","refs":[]},{"group":"regulatory","date":"2025-06-01","precision":"day","title":"Camizestrant: filing (US)","note":"NDA based on SERENA-6","from":"camizestrant","refs":[]},{"group":"regulatory","date":"2025-06-23","precision":"day","title":"Datopotamab deruxtecan: approval (US)","note":"EGFR-mutant NSCLC after TKI and platinum chemotherapy (accelerated)","from":"datopotamab-deruxtecan","refs":[]},{"group":"regulatory","date":"2025-06-27","precision":"day","title":"Tisagenlecleucel: label change (US)","note":"REMS requirements removed for approved CAR-T products","from":"tisagenlecleucel","refs":[]},{"group":"regulatory","date":"2025-07-02","precision":"day","title":"Glofitamab: complete response letter (US)","note":"Complete response letter for STARGLO combination (regional heterogeneity); approved in EU","from":"glofitamab","refs":[]},{"group":"regulatory","date":"2025-07-02","precision":"day","title":"Linvoseltamab: approval (US)","note":"Accelerated approval (LINKER-MM1)","from":"linvoseltamab","refs":[]},{"group":"expected","date":"2025-07-07","precision":"day","title":"FIGHT-302: primary completion","note":"Actual primary completion date on ClinicalTrials.gov.","from":"fight-302","refs":[]},{"group":"regulatory","date":"2025-07-22","precision":"day","title":"Vusolimogene oderparepvec: complete response letter (US)","note":"Complete response letter citing trial design and heterogeneity","from":"vusolimogene-oderparepvec","refs":[]},{"group":"regulatory","date":"2025-07-23","precision":"day","title":"Belantamab mafodotin: complete response letter (US)","note":"Complete response letter on combination filing; resubmitted","from":"belantamab-mafodotin","refs":[]},{"group":"regulatory","date":"2025-07-30","precision":"day","title":"Odronextamab: approval (US)","note":"Accelerated approval in follicular lymphoma","from":"odronextamab","refs":[]},{"group":"regulatory","date":"2025-08","precision":"month","title":"Afamitresgene autoleucel: filing (US)","note":"US rights sold by Adaptimmune to US WorldMeds","from":"afamitresgene-autoleucel","refs":[]},{"group":"regulatory","date":"2025-08-04","precision":"day","title":"Letetresgene autoleucel: filing (US)","note":"Asset transferred to US WorldMeds; BLA committed by end-2026","from":"letetresgene-autoleucel","refs":[]},{"group":"regulatory","date":"2025-08-08","precision":"day","title":"Zongertinib: approval (US)","note":"Accelerated approval, previously treated HER2-mutant non-squamous NSCLC (Beamion LUNG-1)","from":"zongertinib","refs":[]},{"group":"regulatory","date":"2025-08-14","precision":"day","title":"ArteraAI Prostate: approval (US)","note":"De novo authorisation: first AI pathology test cleared for prognostic and predictive use in localised prostate cancer","from":"artera-ai-prostate","refs":[]},{"group":"expected","date":"2025-09","precision":"month","title":"BESPOKE CRC: registry status not updated since a listed completion of September 2025; watch for the primary publication","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["bespoke-crc","signatera"]},{"group":"guideline","date":"2025-09","precision":"month","title":"NCCN 2025 update for HER2-positive breast cancer","note":"1 row added. Anchored to FDA approval of trastuzumab deruxtecan with pertuzumab in the first line, 2025 (DESTINY-Breast09).","from":"breast-her2-positive","refs":["trastuzumab-deruxtecan","pertuzumab","destiny-breast09"]},{"group":"guideline","date":"2025-09","precision":"month","title":"NCCN 2025 updates for Bladder & urothelial cancer","note":"2 rows added. Anchored to FDA approvals of perioperative durvalumab with gemcitabine-cisplatin (March 2025, NIAGARA) and the TAR-200 intravesical gemcitabine system for BCG-unrespo...","from":"urothelial","refs":["durvalumab","gemcitabine-cisplatin","niagara","tar-200"]},{"group":"guideline","date":"2025-09","precision":"month","title":"NCCN 2025 updates for HR-positive / HER2-negative breast cancer","note":"1 row recategorised, 1 row added. Anchored to FDA approvals of trastuzumab deruxtecan for HER2-low or ultralow disease after endocrine therapy (January 2025, DESTINY-Breast06) and...","from":"breast-hr-positive","refs":["trastuzumab-deruxtecan","destiny-breast06","destiny-breast04","imlunestrant"]},{"group":"regulatory","date":"2025-09","precision":"month","title":"Amivantamab: approval (US)","note":"Subcutaneous formulation (PALOMA-3)","from":"amivantamab","refs":[]},{"group":"regulatory","date":"2025-09","precision":"month","title":"Pembrolizumab: approval (US)","note":"Subcutaneous pembrolizumab (Keytruda Qlex)","from":"pembrolizumab","refs":[]},{"group":"regulatory","date":"2025-09","precision":"month","title":"Satricabtagene autoleucel: approval (China)","note":"First CAR-T approved for a solid tumour (CLDN18.2+ gastric/GEJ adenocarcinoma)","from":"satricabtagene-autoleucel","refs":[]},{"group":"regulatory","date":"2025-09-09","precision":"day","title":"Gemcitabine intravesical system (TAR-200): approval (US)","note":"FDA approval of Inlexzo","from":"tar-200","refs":[]},{"group":"expected","date":"2025-09-10","precision":"day","title":"POLCAGB primary completion: neoadjuvant chemoradiation vs chemotherapy in locally advanced gallbladder cancer (124 participants; study completion listed as 10 S...","note":"Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.","from":"gallbladder-cancer-roadmap","refs":["polcagb","chemoradiation"]},{"group":"regulatory","date":"2025-09-25","precision":"day","title":"Imlunestrant: approval (US)","note":"Approved as Inluriyo","from":"imlunestrant","refs":[]},{"group":"expected","date":"2025-09-30","precision":"day","title":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors: primary completion","note":"Actual primary completion date on ClinicalTrials.gov.","from":"nct05208047","refs":[]},{"group":"guideline","date":"2025-10","precision":"month","title":"NCCN 2025 update for Multiple myeloma","note":"1 row added. Anchored to FDA re-approval of belantamab mafodotin in combination, October 2025 (DREAMM-7, DREAMM-8), after the 2022 withdrawal.","from":"multiple-myeloma","refs":["belantamab-mafodotin","dreamm-7","dreamm-8"]},{"group":"regulatory","date":"2025-10","precision":"month","title":"Belantamab mafodotin: approval (US)","note":"Approval in combination regimens for relapsed/refractory myeloma after ≥1 line (DREAMM-7/8)","from":"belantamab-mafodotin","refs":[]},{"group":"regulatory","date":"2025-10","precision":"month","title":"Cemiplimab: approval (US)","note":"Adjuvant high-risk CSCC after surgery and radiation (C-POST)","from":"cemiplimab","refs":[]},{"group":"regulatory","date":"2025-10","precision":"month","title":"Revumenib: approval (US)","note":"Relapsed/refractory NPM1-mutant AML","from":"revumenib","refs":[]},{"group":"regulatory","date":"2025-10-02","precision":"day","title":"Lurbinectedin: approval (US)","note":"Full approval with atezolizumab as first-line maintenance (IMforte)","from":"lurbinectedin","refs":[]},{"group":"guideline","date":"2025-11","precision":"month","title":"NCCN 2024-2025 updates for Acute myeloid leukaemia","note":"2 rows added. Anchored to FDA approvals of revumenib for KMT2A-rearranged acute leukaemia (November 2024, AUGMENT-101) and ziftomenib for NPM1-mutated AML (2025, KOMET-001).","from":"aml","refs":["revumenib","augment-101","ziftomenib","komet-001"]},{"group":"regulatory","date":"2025-11","precision":"month","title":"Durvalumab: approval (US)","note":"Perioperative gastric/GEJ cancer with FLOT (MATTERHORN)","from":"durvalumab","refs":[]},{"group":"regulatory","date":"2025-11-13","precision":"day","title":"Ziftomenib: approval (US)","note":"KOMET-001; priority review","from":"ziftomenib","refs":[]},{"group":"expected","date":"2025-12","precision":"month","title":"ACTICCA-1 primary completion: adjuvant gemcitabine-cisplatin vs capecitabine after resection of cholangiocarcinoma and muscle-invasive gallbladder cancer (789 p...","note":"Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.","from":"gallbladder-cancer-roadmap","refs":["acticca-1","bilcap","capecitabine","gemcitabine-cisplatin"]},{"group":"regulatory","date":"2025-12","precision":"month","title":"Disitamab vedotin: filing (China)","note":"First-line urothelial cancer with toripalimab, positive phase 3","from":"disitamab-vedotin","refs":[]},{"group":"regulatory","date":"2025-12","precision":"month","title":"Tarlatamab: approval (US)","note":"Full approval based on DeLLphi-304","from":"tarlatamab","refs":[]},{"group":"regulatory","date":"2025-12","precision":"month","title":"Zanidatamab: filing (US)","note":"First-line HER2+ gastro-oesophageal adenocarcinoma (HERIZON-GEA-01) submission","from":"zanidatamab","refs":[]},{"group":"regulatory","date":"2025-12-03","precision":"day","title":"Pirtobrutinib: approval (US)","note":"Traditional approval; label broadened to any prior covalent BTKi","from":"pirtobrutinib","refs":[]},{"group":"regulatory","date":"2025-Q4","precision":"quarter","title":"Enfortumab vedotin: filing (US)","note":"Muscle-invasive bladder cancer (EV-303/304) submissions following positive results","from":"enfortumab-vedotin","refs":[]}]},"route":"/years/2025/","neighbours":{"year":[{"id":"2024","kind":"year","name":"2024 in oncology","route":"/years/2024/"},{"id":"2026","kind":"year","name":"2026 in oncology","route":"/years/2026/"}]}}